AB 159: Investigational drugs, biological products, and devices.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2015-09-04
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with an immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with an immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with a serious or an immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with a serious or immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device. The bill would prohibit an official, employee, or agent of the state from blocking an eligible patients access to the investigational drug, biological product, or device pursuant to the bills provisions.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with a serious or immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device. The bill would prohibit an official, employee, or agent of the state from blocking an eligible patients access to the investigational drug, biological product, or device pursuant to the bills provisions.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with a serious or immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care. protocol approved by the physicians institutional review board or an accredited institutional review board, and would require the institutional review board to biannually report specified information to the State Department of Public Health, among others. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device. The bill would prohibit an official, employee, or agent of the state from blocking an eligible patients access to the investigational drug, biological product, or device pursuant to the bills provisions.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the federal United States Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with terminal illnesses, a serious or immediately life-threatening disease or condition, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device. The bill would prohibit an official, employee, or agent of the state from blocking an eligible patients access to the investigational drug, biological product, or device pursuant to the bills provisions.
Existing law, the federal Food, Drug, and Cosmetic Act, prohibits a person from introducing into interstate commerce any new drug unless the drug has been approved by the federal Food and Drug Administration (FDA). Existing law requires the sponsor of a new drug to submit to the FDA an investigational new drug application and to then conduct a series of clinical trials to establish the safety and efficacy of the drug in human populations and submit the results to the FDA in a new drug application.
Existing law, the Sherman Food, Drug, and Cosmetic Law, regulates the packaging, labeling, and advertising of drugs and devices and is administered by the State Department of Public Health. A violation of that law is a crime. The Sherman Food, Drug, and Cosmetic Law prohibits, among other things, the sale, delivery, or giving away of a new drug or new device unless either the department has approved a new drug or device application for that new drug or new device and that approval has not been withdrawn, terminated, or suspended or the drug or device has been approved pursuant to specified provisions of federal law, including the federal Food, Drug, and Cosmetic Act.
The Medical Practice Act provides for the licensure and regulation of physicians and surgeons by the Medical Board of California and requires the board to take action against a licensee who is charged with unprofessional conduct. The Osteopathic Act provides for the licensure and regulation of osteopathic physicians and surgeons by the Osteopathic Medical Board of California and requires the board to enforce the Medical Practice Act with respect to its licensees.
This bill would permit a manufacturer of an investigational drug, biological product, or device to make the product available to eligible patients with terminal illnesses, as specified. The bill would authorize, but not require, a health benefit plan, as defined, to provide coverage for any investigational drug, biological product, or device made available pursuant to these provisions. The bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care. The bill would prohibit a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device. The bill would prohibit an official, employee, or agent of the state from blocking an eligible patients access to the investigational drug, biological product, or device pursuant to the bills provisions.
This article shall be known and may be cited as the Right to Try Act.
111548.1.For purposes of this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who performs all of the following:
(1)Examines the qualified individual and his or her relevant medical records.
(2)Confirms, in writing, the primary physicians diagnosis and prognosis.
(3)Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has an immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has not been accepted to participate in the nearest clinical trial to his or her home for the immediately life-threatening disease or condition identified in paragraph (1) within one week of completion of the clinical trial application process, or, in the treating physicians medical judgment, it is unreasonable for the patient to participate in that clinical trial due to the patients current condition and stage of disease.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(c)Health benefit plan means a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(d)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months.
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or when the patient lacks the capacity to consent his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(5)The success or failure of the investigational drug, biological product, or device in treating the immediately life-threatening disease or condition from which the patient suffers.
(6)Any adverse event for each investigational drug, biological product, or device.
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(d)A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.For purposes of this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who performs all of the following:
(1)Examines the qualified individual and his or her relevant medical records.
(2)Confirms, in writing, the primary physicians diagnosis and prognosis.
(3)Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has an immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that participate in the nearest clinical trial to his or her home for the immediately life-threatening disease or condition identified in paragraph (1) within one week of completion of the clinical trial application process. process, or, in the treating physicians medical judgment, it is unreasonable for the patient to participate in that clinical trial due to the patients current condition and stage of disease.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(c)Health benefit plan means a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(d)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months.
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or when the patient lacks the capacity to consent his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(5)The success or failure of the investigational drug, biological product, or device in treating the immediately life-threatening disease or condition from which the patient suffers.
(6)Any adverse event for each investigational drug, biological product, or device.
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(d)A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.For purposes of this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who performs all of the following:
(1)Examines the qualified individual and his or her relevant medical records.
(2)Confirms, in writing, the primary physicians diagnosis and prognosis.
(3)Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has a serious or an immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the serious or immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(c)Health benefit plan means a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(d)(1)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment. months.
(2)Serious disease or condition means a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the serious or immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or when the patient lacks the capacity to consent his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(5)The success or failure of the investigational drug, biological product, or device in treating the serious or immediately life-threatening disease or condition from which the patient suffers.
(6)Any adverse event for each investigational drug, biological product, or device.
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(d)A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.For purposes of this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who performs all of the following:
(A)
(1)Examines the qualified individual and his or her relevant medical records.
(B)
(2)Confirms, in writing, the primary physicians diagnosis and prognosis.
(C)
(3)Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has a serious or immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the serious or immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(c)Health benefit plan means a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(d)(1)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
(2)Serious disease or condition means a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the serious or immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or when the patient lacks the capacity to consent his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand or otherwise affect the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(5)The success or failure of the investigational drug, biological product, or device in treating the serious or immediately life-threatening disease or condition from which the patient suffers.
(6)Any adverse event for each investigational drug, biological product, or device.
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(d)An official, employee, or agent of this state shall not block or attempt to block an eligible patients access to an investigational drug, biological product, or device pursuant to this article. Counseling, advice, or a recommendation consistent with medical standards of care from an individual licensed under Division 2 (commencing with Section 500) of the Business and Professions Code shall not be considered a violation of this section.
(e)
(d)A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.In For purposes of this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who shall perform performs all of the following:
(A)Examine Examines the qualified individual and his or her relevant medical records.
(B)Confirm Confirms, in writing writing, the primary physicians diagnosis and prognosis.
(C)Verify, Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has a serious or immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the serious or immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(c)Health benefit plan means any a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345 of this code, 1345, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(d)(1)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
(2)Serious disease or condition means a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the serious or immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or when the patient lacks the capacity to consent, consent his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand or otherwise affect the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that device if the recommendation or prescription is consistent with protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(d)An official, employee, or agent of this state shall not block or attempt to block an eligible patients access to an investigational drug, biological product, or device pursuant to this article. Counseling, advice, or a recommendation consistent with medical standards of care from an individual licensed under Division 2 (commencing with Section 500) of the Business and Professions Code shall not be considered a violation of this section.
(e) A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action action, and actions taken pursuant to this article shall not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, for any harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, so long as or the use or nonuse thereof, if the manufacturer or other person or entity is complying in good faith has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.In this article, unless the context otherwise requires, the following definitions shall apply:
(a)Consulting physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who shall perform all of the following:
(A)Examine the qualified individual and his or her relevant medical records.
(B)Confirm in writing the primary physicians diagnosis and prognosis.
(C)Verify, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
(a)
(b)Eligible patient means a person who meets all of the following conditions:
(1)Has a serious or immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the serious or immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her primary physician and a consulting physician attesting that the patient has met the requirements of this subdivision.
(b)
(c)Health benefit plan means any plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345 of this code, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(c)
(d)(1)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
(2)Serious disease or condition means a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
(d)
(e)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(e)Physician
(f)Primary physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(f)
(g)State regulatory board means the Medical Board of California or the Osteopathic Medical Board of California.
(g)
(h)(1)Written, informed consent means a written document that has been approved by the primary physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative where when the patient lacks the capacity to consent, and attested to by the patients primary physician and a witness that, at a minimum, does all of the following:
(A)Explains the currently approved products and treatments for the serious or immediately life-threatening disease or condition from which the patient suffers.
(B)Attests to the fact that the patient, or where when the patient lacks the capacity to consent, his or her legally authorized representative, concurs with the patients primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the primary physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(G)Clearly states that in-home health care may be denied if treatment begins.
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand or otherwise affect the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If the clinical trial for an investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity, the investigational drug, biological product, or device shall not be offered. If notice is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patients primary physician shall notify the patient of the information from the safety committee of the clinical trial.
(d)
(e)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care. protocol approved by the physicians institutional review board or an accredited independent institutional review board.
(b)The physicians institutional review board or an accredited institutional review board shall biannually report the following information to the State Department of Public Health, the Medical Board of California, and the Osteopathic Medical Board of California:
(1)The number of requests made for an investigational drug, biological product, or device.
(2)The status of the requests made.
(3)The duration of the treatment.
(4)The costs of the treatment paid by eligible patients.
(b)
(c)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(c)
(d)An official, employee, or agent of this state shall not block or attempt to block an eligible patients access to an investigational drug, biological product, or device pursuant to this article. Counseling, advice, or a recommendation consistent with medical standards of care from an individual licensed under Division 2 (commencing with Section 500) of the Business and Professions Code shall not be considered a violation of this section.
(d)
(e) A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.In this article, unless the context otherwise requires, the following definitions shall apply:
(a)Eligible patient means a person who meets all of the following conditions:
(1)Has a terminal illness. serious or immediately life-threatening disease or condition.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the terminal illness serious or immediately life-threatening disease or condition identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her physician attesting that the patient has met the requirements of this subdivision.
(b)Health benefit plan means any plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345 of this code, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(c)(1)Immediately life-threatening disease or condition means a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
(2)Serious disease or condition means a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
(c)
(d)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(d)
(e)Physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(e)
(f)State regulatory board means the California Medical Board of California or the Osteopathic Medical Board of California.
(f)Terminal illness means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.
(g)(1)Written, informed consent means a written document that has been approved by the physicians institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative where the patient lacks the capacity to consent, and attested to by the patients physician and a witness that, at a minimum, does all of the following:
(1)
(A)Explains the currently approved products and treatments for the terminal illness serious or immediately life-threatening disease or condition from which the patient suffers.
(2)
(B)Attests to the fact that the patient, or where the patient lacks the capacity to consent, his or her legally authorized representative, concurs with the patients physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(3)
(C)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(4)
(D)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(5)
(E)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(6)
(F)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(7)
(G)Clearly states that in-home health care may be denied if treatment begins.
(8)
(H)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
(2)Written, informed consent for purposes of this article shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act (Chapter 1.3 (commencing with Section 24170) of Division 20).
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand or otherwise affect the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care.
(b)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(c)An official, employee, or agent of this state shall not block or attempt to block an eligible patients access to an investigational drug, biological product, or device pursuant to this article. Counseling, advice, or a recommendation consistent with medical standards of care from an individual licensed under Division 2 (commencing with Section 500) of the Business and Professions Code shall not be considered a violation of this section.
(d) A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
This article shall be known and may be cited as the Right to Try Act.
111548.1.In this article, unless the context otherwise requires, the following definitions shall apply:
(a)Eligible patient means a person who meets all of the following conditions:
(1)Has a terminal illness.
(2)Has considered all other treatment options currently approved by the United States Food and Drug Administration.
(3)Has been unable to participate in a clinical trial for the terminal illness identified in paragraph (1) within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process.
(4)Has received a recommendation from his or her physician for an investigational drug, biological product, or device.
(5)Has given written informed consent for the use of the investigational drug, biological product, or device, or if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf.
(6)Has documentation from his or her physician attesting that the patient has met the requirements of this subdivision.
(b)Health benefit plan means any plan or program that provides, arranges, pays for, or reimburses the cost of health benefits. Health benefit plan includes, but is not limited to, a health care service plan contract issued by a health care service plan, as defined in Section 1345 of this code, and a policy of health insurance, as defined in Section 106 of the Insurance Code, issued by a health insurer.
(c)Investigational drug, biological product, or device means a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration, but has not been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration.
(d)Physician means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
(e)State regulatory board means the California Medical Board or the Osteopathic Medical Board of California.
(f)Terminal illness means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.
(g)Written, informed consent means a written document that is signed by an eligible patient, or his or her legally authorized representative where the patient lacks the capacity to consent, and attested to by the patients physician and a witness that, at a minimum, does all of the following:
(1)Explains the currently approved products and treatments for the terminal illness from which the patient suffers.
(2)Attests to the fact that the patient, or where the patient lacks the capacity to consent, his or her legally authorized representative, concurs with the patients physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patients life.
(3)Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
(4)Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome. This description shall include the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. The description shall be based on the physicians knowledge of the proposed treatment in conjunction with an awareness of the patients condition.
(5)Clearly states that the patients health benefit plan, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device.
(6)Clearly states that the patients eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
(7)Clearly states that in-home health care may be denied if treatment begins.
(8)States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patients estate, except as otherwise provided in the patients health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
111548.2.(a)Notwithstanding Section 110280, 111520, or 111550, a manufacturer of an investigational drug, biological product, or device may make available the manufacturers investigational drug, biological product, or device to an eligible patient pursuant to this article. This article does not require that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
(b)A manufacturer may do both of the following:
(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.
(2)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
(c)(1)This article does not expand or otherwise affect the coverage provided under Sections 1370.4 and 1370.6 of this code, Sections 10145.3 and 10145.4 of the Insurance Code, or Sections 14087.11 and 14132.98 of the Welfare and Institutions Code.
(2)This article does not require a health benefit plan to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this article. A health benefit plan may provide coverage for an investigational drug, biological product, or device made available pursuant to this section.
(d)If an eligible patient dies while being treated by an investigational drug, biological product, or device made available pursuant to this article, the patients heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
111548.3.(a)Notwithstanding any other law, a state regulatory board shall not revoke, fail to renew, or take any other disciplinary action against a physicians license based solely on the physicians recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device, provided that the recommendation or prescription is consistent with medical standards of care.
(b)A state agency shall not alter any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care providers certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
(c)An official, employee, or agent of this state shall not block or attempt to block an eligible patients access to an investigational drug, biological product, or device pursuant to this article. Counseling, advice, or a recommendation consistent with medical standards of care from an individual licensed under Division 2 (commencing with Section 500) of the Business and Professions Code shall not be considered a violation of this section.
(d) A violation of this section shall not be subject to Chapter 8 (commencing with Section 111825).
111548.5.This article does not create a private cause of action against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
|
Date
|
Status
|
|---|---|
| Jan 15, 2016 | Consideration of Governor's veto stricken from file. |
| Oct 11, 2015 | Vetoed by Governor. |
| Sep 14, 2015 | Enrolled and presented to the Governor at 4 p.m. |
| Sep 2, 2015 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 76. Noes 2. Page 2799.). |
| Sep 2, 2015 | Assembly Rule 77 suspended. (Page 2795.) |
| Sep 2, 2015 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 76. Noes 2.). |
| Sep 2, 2015 | Assembly Rule 77 suspended. |
| Sep 1, 2015 | Read third time. Passed. Ordered to the Assembly. (Ayes 40. Noes 0. Page 2344.). |
| Sep 1, 2015 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 3 pursuant to Assembly Rule 77. |
| Sep 1, 2015 | Read third time. Passed. Ordered to the Assembly. |
| Aug 31, 2015 | Read second time. Ordered to third reading. |
| Aug 27, 2015 | From committee: Do pass. (Ayes 7. Noes 0.) (August 27). |
| Jul 13, 2015 | In committee: Referred to suspense file. |
| Jul 6, 2015 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on APPR. |
| Jun 30, 2015 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 29). Re-referred to Com. on APPR. |
| Jun 19, 2015 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B., P. & E.D. |
| Jun 16, 2015 | Read second time and amended. Re-referred to Com. on B., P. & E.D. |
| Jun 15, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on B., P. & E.D. (Ayes 8. Noes 0.) (June 10). |
| Jun 1, 2015 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| May 28, 2015 | Referred to Coms. on HEALTH and B., P. & E.D. |
| May 18, 2015 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 18, 2015 | Read third time. Passed. Ordered to the Senate. (Ayes 74. Noes 2. Page 1485.) |
| May 18, 2015 | Read third time. Passed. Ordered to the Senate. |
| May 14, 2015 | Read second time. Ordered to third reading. |
| May 13, 2015 | From committee: Do pass. (Ayes 15. Noes 0.) (May 13). |
| Apr 29, 2015 | Re-referred to Com. on APPR. |
| Apr 28, 2015 | Read second time and amended. |
| Apr 27, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 21). |
| Apr 14, 2015 | Re-referred to Com. on B. & P. |
| Apr 13, 2015 | Read second time and amended. |
| Apr 9, 2015 | From committee: Amend, and do pass as amended and re-refer to Com. on B. & P. (Ayes 17. Noes 0.) (April 7). |
| Feb 2, 2015 | Referred to Coms. on HEALTH and B. & P. |
| Jan 22, 2015 | From printer. May be heard in committee February 21. |
| Jan 21, 2015 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 2, 2015 | AB 159 CALDERON Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 1, 2015 | Assembly 3rd Reading AB159 Calderon By Stone | Senate Floor |
Passed |
|
| Aug 27, 2015 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 13, 2015 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 29, 2015 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| Jun 10, 2015 | Do pass as amended, but first amend, and re-refer to the Committee on [Business, Professions and Economic Development] | Senate Standing Committee on Health |
Passed |
|
| May 18, 2015 | AB 159 CALDERON Assembly Third Reading | Assembly Floor |
Passed |
|
| May 13, 2015 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2015 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
|
| Apr 7, 2015 | Do pass as amended and be re-referred to the Committee on [Business and Professions] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
GOVERNOR'S VETO
AB 159
(Calderon)
As Enrolled September 4, 2015
2/3 vote
ASSEMBLY: |
74-2 |
(May 18, 2015) |
SENATE: |
40-0 |
(September 1, 2015) |
ASSEMBLY: |
76-2 |
(September 2, 2015) |
|
|
|
Original Committee Reference: HEALTH
SUMMARY: Authorizes the manufacturer of an investigational drug to make an investigational drug that is not yet approved by the United States Food and Drug Administration (FDA) available to a patient, under certain circumstances.
The Senate amendments limit the patients able to participate to those with an immediately life-threatening disease or condition, adds types of information about the treatment that is reported by the institutional review board to agencies collecting the data, removes language prohibiting an official, employee, or agent of this state from blocking or attempting to block an eligible patient's access to an investigational drug or device, and clarifies language stating that this bill does not create a private right of action including but not limited to, product liability, medical negligence, or wrongful death against a physician or manufacturer involved in the use of an investigational drug pursuant to this bill.
EXISTING STATE LAW prohibits, under the Sherman Food, Drug, and Cosmetic Law, the sale, delivery, or giving away of a drug or device unless it has been approved to market by either the FDA or the California Department of Public Health.
EXISTING FEDERAL LAW prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
FISCAL EFFECT: According to the Senate Appropriations Committee, one-time costs of $20,000 and ongoing costs of $10,000 per year to review plan filings by the Department of Insurance (Insurance Fund). Additionally, one-time costs of $380,000 in 2015-16 to respond to requests for information about prior independent medical review decisions and ongoing costs of $210,000 per year to respond to consumer complaints and requests for independent medical review for access to investigational drugs by the Department of Managed Health Care (Managed Care Fund). Uncertain impact on state-funded CalPERS health care coverage (General Fund and special funds).
COMMENTS: According to the author, this bill removes barriers to accessing potentially life-saving drugs for terminally-ill patients and doctors who believe an investigational drug or device could be their last hope for survival. These patients may seek compassionate use exemptions from the FDA, but the process is cumbersome and approval comes too late for many. The author asserts that this bill removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
A clinical trial is a study that is carefully designed to test the benefits and risks of a specific medical treatment or intervention, such as a new drug. The FDA requires a multi-phase clinical trials process to be completed before deciding if an investigational medicine is safe and effective for a broader patient population. Experimental drugs and devices go through clinical trials, stage one of which establishes very basic safety level and assesses toxicity. Once a drug or device passes stage one, there are two more phases before being approved for sale. This bill would allow manufacturers to make available investigational products, that have passed phase one trials, to patients meeting specified criteria, and would protect from liability doctors who recommend or prescribe the investigational products, as well as manufacturers who make them available.
Patients who are not eligible for a clinical trial because of where they live, their age, or some other disqualifying factor have the option to seek expanded access if they have serious or life-threatening conditions and no comparable or satisfactory alternative is available. The FDA has in place processes to allow patients access: expanded access, which is sometimes called "compassionate use," supplements the clinical trials process. A licensed physician is able to apply for expanded access on behalf of the patient. The FDA states that they receive approximately 1,000 expanded use applications per year, and has approved more than 99% of those applications. In the last four years, the FDA has denied only 33 of nearly 6,000 expanded access requests. Emergency requests are often granted immediately over the phone. For non-emergencies, the FDA states that they strive to respond promptly and, in general, approve the request within 30 days.
Critics of the FDA process have raised concerns that the expanded access application is too cumbersome for physicians and patients to complete. Critics claim that it currently requires an application that takes doctors 100 hours to fill out. On February 4, 2015, the FDA announced that it would be streamlining the expanded use application process, and stated that the proposed application will allow physicians to apply for experimental drugs in just 45 minutes. The FDA draft guidance on the new application process is currently in the public comment period and the new final rule should be released shortly.
The Los Angeles County Board of Supervisors supports this bill, stating that seriously ill patients who have exhausted their options to find a cure and who have identified physicians and a pharmaceutical company willing to assist them, deserve the right to experimental treatments that could improve their health conditions or prolong their lives.
The California Nurses Association/National Nurses United (CNA) and the Association of Northern California Oncologists (ANCO) oppose this bill, citing patient safety and other concerns. ANCO states that this bill threatens the viability of adult clinical trial enrollment and would result in slowing the development of cancer care in the future. CNA points out that "nothing in this legislation impacts the availability of drugs to terminally ill patients unless the manufacturers of the drugs allow it to be used in advance of FDA approval". If a manufacturer provided an experimental drug or device to a patient without FDA approval under this law, they would be in direct violation of federal law.
This bill would permit a pharmaceutical manufacturer to make an investigational drug available to a patient with an immediately life-threatening disease on the recommendation of two physicians.
Patients with life threatening conditions should be able to try experimental drugs, and the United States Food and Drug Administration's compassionate use program allows this to happen. The proposed changes to this program will streamline access to these drugs. Before authorizing an alternative state pathway, we should give this federal expedited process a chance to work.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN: 0002503
AB 159
Page 2
CONCURRENCE IN SENATE AMENDMENTS
AB 159
(Calderon)
As Amended July 6, 2015
Majority vote
ASSEMBLY: |
74-0 |
(May 18, 2015) |
SENATE: |
40-0 |
(September 1, 2015) |
Original Committee Reference: HEALTH
SUMMARY: Authorizes the manufacturer of an investigational drug to make an investigational drug that is not yet approved by the United States Food and Drug Administration (FDA) available to a patient, under certain circumstances.
The Senate amendments limit the patients able to participate to those with an immediately life-threatening disease or condition, adds types of information about the treatment that is reported by the institutional review board to agencies collecting the data, removes language prohibiting an official, employee, or agent of this state from blocking or attempting to block an eligible patient's access to an investigational drug or device, and clarifies language stating that this bill does not create a private right of action including but not limited to, product liability, medical negligence, or wrongful death against a physician or manufacturer involved in the use of an investigational drug pursuant to this bill.
EXISTING STATE LAW prohibits, under the Sherman Food, Drug, and Cosmetic Law, the sale, delivery, or giving away of a drug or device unless it has been approved to market by either the FDA or the California Department of Public Health.
EXISTING FEDERAL LAW prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
FISCAL EFFECT: According to the Senate Appropriations Committee, one-time costs of $20,000 and ongoing costs of $10,000 per year to review plan filings by the Department of Insurance (Insurance Fund). Additionally, one-time costs of $380,000 in 2015-16 to respond to requests for information about prior independent medical review decisions and ongoing costs of $210,000 per year to respond to consumer complaints and requests for independent medical review for access to investigational drugs by the Department of Managed Health Care (Managed Care Fund). Uncertain impact on state-funded CalPERS health care coverage (General Fund and special funds).
COMMENTS: According to the author, this bill removes barriers to accessing potentially life-saving drugs for terminally-ill patients and doctors who believe an investigational drug or device could be their last hope for survival. These patients may seek compassionate use exemptions from the FDA, but the process is cumbersome and approval comes too late for many. This bill removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
A clinical trial is a study that is carefully designed to test the benefits and risks of a specific medical treatment or intervention, such as a new drug. The FDA requires a multi-phase clinical trials process to be completed before deciding if an investigational medicine is safe and effective for a broader patient population. Experimental drugs and devices go through clinical trials, stage one of which establishes very basic safety level and assesses toxicity. Once a drug or device passes stage one, there are two more phases before being approved for sale. This bill would allow manufacturers to make available investigational products, that have passed phase one trials, to patients meeting specified criteria, and would protect from liability doctors who recommend or prescribe the investigational products, as well as manufacturers who make them available.
Patients who are not eligible for a clinical trial because of where they live, their age, or some other disqualifying factor have the option to seek expanded access if they have serious or life-threatening conditions and no comparable or satisfactory alternative is available. The FDA has in place processes to allow patients access: expanded access, which is sometimes called "compassionate use," supplements the clinical trials process. A licensed physician is able to apply for expanded access on behalf of the patient. The FDA states that they receive approximately 1,000 expanded use applications per year, and has approved more than 99% of those applications. In the last four years, the FDA has denied only 33 of nearly 6,000 expanded access requests. Emergency requests are often granted immediately over the phone. For non-emergencies, the FDA states that they strive to respond promptly and, in general, approve the request within 30 days.
Critics of the FDA process have raised concerns that the expanded access application is too cumbersome for physicians and patients to complete. Critics claim that it currently requires an application that takes doctors 100 hours to fill out. On February 4, 2015, the FDA announced that it would be streamlining the expanded use application process, and stated that the proposed application will allow physicians to apply for experimental drugs in just 45 minutes. The FDA draft guidance on the new application process is currently in the public comment period and the new final rule should be released shortly.
The Los Angeles County Board of Supervisors supports this bill, stating that seriously ill patients who have exhausted their options to find a cure and who have identified physicians and a pharmaceutical company willing to assist them, deserve the right to experimental treatments that could improve their health conditions or prolong their lives.
The California Nurses Association/National Nurses United (CNA) and the Association of Northern California Oncologists (ANCO) oppose this bill, citing patient safety and other concerns. ANCO states that this bill threatens the viability of adult clinical trial enrollment and would result in slowing the development of cancer care in the future. CNA points out that "nothing in this legislation impacts the availability of drugs to terminally ill patients unless the manufacturers of the drugs allow it to be used in advance of FDA approval". If a manufacturer provided an experimental drug or device to a patient without FDA approval under this law, they would be in direct violation of federal law.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN: 0001905
AB 159
Page 8
|
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 |
THIRD READING
Bill No: AB 159
Amended: 7/6/15 in Senate
SENATE HEALTH COMMITTEE: 8-0, 6/10/15
AYES: Hernandez, Nguyen, Hall, Mitchell, Monning, Pan, Roth, Wolk
NO VOTE RECORDED: Nielsen
SENATE BUS, PROF. & ECON. DEV. COMMITTEE: 8-0, 6/29/15
AYES: Hill, Bates, Block, Galgiani, Hernandez, Jackson, Mendoza, Wieckowski
NO VOTE RECORDED: Berryhill
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/27/15
AYES: Lara, Bates, Beall, Hill, Leyva, Mendoza, Nielsen
ASSEMBLY FLOOR: 74-2, 5/18/15 - See last page for vote
SUBJECT: Investigational drugs, biological products, and devices
DIGEST: This bill permits a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. Prohibits this bill from requiring that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
Existing law:
Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), which regulates the packaging, labeling, and advertising of drugs and devices, administered by the Department of Public Health (DPH). Prohibits, in the Sherman Law, the sale, delivery, or giving away of a new drug or device unless it is either:
A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the U.S. Food and Drug Administration (FDA), pursuant to federal law, or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated, or suspended under the FDA.
Establishes the Protection of Human Subjects in Medical Experimentation Act which prescribes various protections for subjects of medical experimentation relating to a bill of rights; informed consent procedures and documentation; and, the provision of specified disclosures, including the right for a subject to give or withdraw consent freely and without duress. Imposes penalties for violations of these protections.
This bill:
Permits a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. Prohibits this bill from requiring that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
Defines “investigational drug, biological product, or device” as a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the FDA, but has not been approved for general use by the United States Department of Agriculture and remains under investigation in a clinical trial approved by the FDA.
Defines “eligible patient” as a person who:
Has an immediately life-threatening disease or condition. Defines “immediately life-threatening disease or condition” as a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months;
Has considered all other treatment options currently approved by the FDA;
Has not been accepted to participate in the nearest clinical trial to his or her home for the immediately life-threatening disease or condition within one week of completion of the clinical trial application process, or, in the treating physician’s medical judgment, it is unreasonable for the patient to participate in that clinical trial due to the patient’s current condition and stage of disease; and,
Has received a recommendation from his or her primary physician and a consulting physician, as defined, for an investigational drug, biological product, or device. Defines “consulting physician” as a physician and surgeon or an osteopathic physician and surgeon who:
Examines the qualified individual and his or her relevant medical records;
Confirms, in writing, the primary physician’s diagnosis and prognosis; and,
Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf. Defines “written informed consent” as a written document that has been approved by the primary physician’s IRB or an accredited independent IRB, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patient’s primary physician and a witness that, at a minimum:
Explains the currently approved products and treatments for the disease or condition from which the patient suffers;
Attests to the fact that the patient, or his or her legally authorized representative, concurs with the primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’s life;
Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use;
Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome, as specified;
Clearly states that the patient’s health plan or insurer, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device;
Clearly states that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements;
Clearly states that in-home health care may be denied if treatment begins; and,
States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patient’s estate, except as otherwise provided in the patient’s health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
Permits a manufacturer to provide an investigational drug, biological product, or device to an eligible patient without receiving compensation and to require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
Prohibits this bill from expanding coverage provided by health plans or insurers, the Medi-Cal program, or county organized health systems.
Specifies that this bill does not require a health plan or insurer to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this bill, but permits one to provide such coverage.
Prohibits an investigational drug, biological product, or device from being offered if a clinical trial for that investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity. Requires the manufacturer and the patient’s primary physician, if notice of closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, to notify the patient of the information from the safety committee of the clinical trial.
Prohibits the heirs of an eligible patient, if he/she dies while being treated by an investigational drug, biological product, or device made available pursuant to this bill, from being liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
Prohibits a state regulatory board from revoking, failing to renew, or taking any other disciplinary action against a physician’s license based solely on the physician’s recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physician’s IRB or an accredited independent institutional review board.
Requires the physician’s IRB or an accredited institutional review board to biannually report to DPH, the Medical Board of California, and the Osteopathic Medical Board of California:
The number of requests made for an investigational drug, biological product, or device;
The status of the requests made;
The duration of the treatment;
The costs of the treatment paid by eligible patients;
The success or failure of the investigational drug, biological product, or device in treating the disease or condition, as specified; and,
Any adverse event for each investigational drug, biological product, or device.
Prohibits a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
Makes a violation of this bill not subject to the Sherman Law.
Specifies that this bill does not create a private cause of action, and that actions taken pursuant to this bill do not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
Comments
Author’s statement. According to the author, terminally ill patients often do not have the luxury of waiting for the FDA to grant compassionate use or participating in the lengthy process of clinical trials. AB 159 gives terminally ill patients a chance to try potentially life-saving treatments after all other options have been exhausted. It removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
Background. According to an April 9, 2015, Health Policy Brief on the issue of right-to-try laws in Health Affairs, under current federal regulations, patients with serious or life-threatening illness have two primary options to access experimental therapies that may treat their condition but that have not yet been approved by the FDA: participate as a human subject in a clinical trial or, for patients who cannot be enrolled in that trial (because of their medical status or geographic location, for example), apply to the FDA for access to the experimental drug under the expanded access (also known as compassionate use) program.
Clinical trials. According to the 2015 Health Affairs brief, clinical testing of an experimental drug is typically a three-phase process. Phase I trials are small (20 to 80 patients) and are used primarily to evaluate safety and dosing ranges, usually in healthy volunteers. Phase II trials are larger (typically 100 to 300 patients) and are designed to show early evidence of efficacy in the patients that the drug is intended to treat. Phase III trials may include hundreds or thousands of patients and are used to demonstrate that the drug is effective compared to a control (such as a placebo). Typically, a manufacturer submits an application to the FDA for marketing approval once a drug has successfully completed Phase III trials. The drug may be only administered to patients who are formally enrolled in that clinical trial. The study population for that trial may be limited based on any number of factors, including specific diagnosis, age, stage of illness, or comorbidities.
Expanded access program. According to the 2015 Health Affairs brief, the expanded access program is an attempt at flexibility in the regulatory process and to allow patients with no other treatment options a chance to try therapies they may not otherwise have access to. The program allows patients who meet certain eligibility requirements to receive an experimental therapy outside of the formal clinical research process. There are three categories of expanded access: treatment, single patient, and intermediate, which are further split into two subcategories. One is “expanded access INDs,” through which the manufacturer submits a separate IND for a patient or group of patients, and the other is “expanded access protocols,” whereby the manufacturer amends the protocol under an existing IND to include the patient (or patients) seeking access. Under treatment INDs, a relatively large group of patients (hundreds or thousands) are permitted to access an experimental drug, provided that the sponsor is actively pursuing FDA approval and is in later stages of testing (or has already submitted trial results to the FDA for review). According to an article published in the January 15, 2015 New England Journal of Medicine (NEJM), the FDA has permitted almost all expanded access requests regardless of category. The FDA estimated that by 2006, approximately 100,000 patients had obtained expanded access to experimental drugs. Between 2010 and 2013, the FDA imposed clinical holds on only two of the 2,472 individual, non-emergency protocols, on one of 66 intermediate-size requests, and on none of the 41 widespread expanded-access protocols it received.
The Health Affairs brief states that critics of the expanded access program have argued that the application process is unnecessarily burdensome and lengthy (it is estimated that the IND application requires about 100 hours to complete), which discourages doctors and manufacturers from applying. An IRB review adds an additional layer of paperwork and potential delay. These requirements were put in place in response to highly publicized incidents of harm caused by unsafe drugs. In the past decade, there have been several attempts made at the federal and judicial levels to further relax restrictions on the administration of experimental therapies to terminally ill patients. One, led by the Abigail Alliance for Better Access to Developmental Drugs, submitted a Citizen Petition to the FDA in 2003 requesting that it make experimental therapies available to terminally ill patients, provided that the drug had passed Phase I testing. Following several years of litigation, the D.C. Court of Appeals ruled against the Abigail Alliance, stating that terminally ill patients have no constitutional right to access experimental therapies.
FDA action. According to an article in the Wall Street Journal published on February 9, 2015, the FDA announced it would “simplify and accelerate” the application process for “unapproved investigational drugs” that have passed Phase I safety trials. It is estimated that the new application form will take 45 minutes to complete, asks attending physicians to fill in eight pieces of patient information, and requires only one attachment. The FDA issued draft guidance and included a copy of the new form, asking for comment until April 13, 2015. The FDA is now in the process of reviewing the public comments and will not likely finalize the guidance before early fall.
NOTE: Please refer to the Senate Health Committee analysis for detailed background on this bill.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
One-time costs of $20,000 and ongoing costs of $10,000 per year to review plan filings by the Department of Insurance (Insurance Fund).
One-time costs of $380,000 in 2015-16 to respond to requests for information about prior independent medical review decisions and ongoing costs of $210,000 per year to respond to consumer complaints and requests for independent medical review for access to investigational drugs by the Department of Managed Health Care (Managed Care Fund).
Uncertain impact on state-funded California Public Employees’ Retirement System health care coverage (General Fund and special funds).
ALS Association Golden West Chapter
Los Angeles County Board of Supervisors
OPPOSITION: (Verified 8/28/15)
Association of Northern California Oncologists
California Nurses Association
California Right to Life Committee, Inc.
ASSEMBLY FLOOR: 74-2, 5/18/15
AYES: Achadjian, Alejo, Travis Allen, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Dahle, Daly, Dodd, Eggman, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Lackey, Linder, Lopez, Low, Maienschein, Mayes, McCarty, Medina, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Perea, Rendon, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Atkins
NOES: Levine, Quirk
NO VOTE RECORDED: Gordon, Kim, Mathis, Melendez
Prepared by: Melanie Moreno / HEALTH /
8/31/15 15:12:22
**** END ****
AB 159 (Calderon) Page 3 of 3
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
AB 159 (Calderon) - Investigational drugs, biological products, and devices
|
|
Version: July 6, 2015 |
Policy Vote: HEALTH 8 - 0, B., P. & E.D. 8 - 0 |
Urgency: No |
Mandate: No |
Hearing Date: July 13, 2015 |
Consultant: Brendan McCarthy |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
AB 159 would authorize the manufacturer of an investigational drug to make an investigational drug available to a patient, under certain circumstances.
Fiscal Impact:
One-time costs of $20,000 and ongoing costs of $10,000 per year to review plan filings by the Department of Insurance (Insurance Fund).
Onet-time costs of $380,000 in 2015-16 to respond to requests for information about prior independent medical review decisions and ongoing costs of $210,000 per year to respond to consumer complaints and requests for independent medical review for access to investigational drugs by the Department of Managed Health Care (Managed Care Fund).
Uncertain impact on state-funded CalPERS health care coverage (General Fund and special funds). (See below.)
Background:
Under federal law and regulation, drug manufacturers must apply to the federal Food and Drug Administration for permission to market drugs. The application process includes a series of clinical trials to demonstrate the safety and effectiveness of new drugs. The clinical trial process includes a variety of requirements regarding informed consent for participants and reporting requirements on manufacturers. Current federal law also includes a process whereby seriously ill patients can access investigational drugs before they have been approved for general use and without the patient needing to be a participant in a clinical trial. In recent years, concerns have been raised that the process for approving such requests is slow and cumbersome for physicians, discouraging them from seeking such access for their seriously ill patients.
Current state law generally prohibits the sale or giving away of new drugs unless the new drug has been approved by the state Department of Public Health or the drug has been approved for use by the federal Food and Drug Administration (including premarket approval). State law authorizes the experimental use of drugs and requires certain patient protections, such as oversight by a review committee and informed consent for the patient.
Current state law authorizes patients to seek an independent medical review when a health plan or health insurer denies coverage for an experimental or investigational drug when the patient has a life-threatening or seriously debilitating condition, the patient’s physician indicates that standard therapies have not been effective, and the patient’s physician has recommended an experimental or investigational drug. If the independent medical review finds that the required conditions are met, the health plan or health insurer is required to provide coverage for the experimental or investigational drug.
Statute governing the state’s Medi-Cal program generally limits the coverage for experimental drugs and prohibits coverage of experimental drugs if the experimental drug costs more than conventional therapies.
Proposed Law:
AB 159 would authorize the manufacturer of an investigational drug to make an investigational drug available to a patient, under certain circumstances.
Specific provisions of the bill would:
Authorize a manufacturer of an investigational drug, biological product, or device to make such product available to an eligible patient;
Authorize a manufacturer to make an investigational product available to a patient without compensation or to require the patient to pay the costs of manufacturing the product;
Specify that the bill does not require a health plan or state agency to provide coverage for the costs of an investigational product;
Authorize a health plan to provide coverage for an investigational product;
Prohibit a state regulatory board from taking disciplinary action against a physician based on the physician’s recommendation that a patient use an investigational product;
Prohibit a state agency from taking regulatory action against a health facility based on a facility’s participation in treatment using an investigational product;
Require a participating physician’s institutional review board or an accredited institutional review board to provide information to the Department of Public Health, the Medical Board, and the Osteopathic Medical Board on the use of investigational drugs under the bill.
Related Legislation:
SB 715 (Anderson) is substantially similar to this bill. That bill is pending in the Senate Health Committee.
AB 149 (Stone) is substantially similar to this bill. That bill is in the Assembly Business and Professions Committee.
Staff Comments:
The bill would authorize a manufacturer to make investigational drugs available to patients under limited circumstances. The bill itself does not require a patient’s health plan to provide coverage for the cost of the investigational drug. However, state law requires health plans to provide coverage for investigational drugs under certain circumstances. If a health plan denies coverage for an investigational drug, an enrollee can request an independent medical review of that decision. Based on the independent medical review, a health plan may be required to provide coverage for an investigational drug. It is possible that patients could use the independent medical review process to access coverage for investigational drugs provided by manufacturers under this bill. To the extent that patients enrolled in coverage provided by CalPERS do so, there could be additional costs to the state and/or local governments.
-- END --
AB 159 (Calderon) Page 10 of 10
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2015 - 2016 Regular
Bill No: AB 159 Hearing Date: June 29, 2015
Author: |
Calderon |
||
Version: |
June 19, 2015 |
||
Urgency: |
No |
Fiscal: |
Yes |
Consultant: |
Sarah Mason |
||
Subject: Investigational drugs, biological products, and devices.
SUMMARY: Permits a manufacturer of a drug, biological product, or device that has not yet received federal or state approval to market to make the product available to eligible patients with an immediate life threatening condition, as specified.
NOTE: This bill was referred to the Senate Committee on Health first, and was passed out of that Committee on June 10, 2015 by a vote of 8-0
Existing federal law:
Establishes the United States Food and Drug Administration (FDA) to protect the public health by assuring the safety, effectiveness, quality, and security of human and veterinary drugs, vaccines and other biological products, and medical devices through the Food, Drug, and Cosmetic Act (FDCA). (21 United States Code (USC) § 301 et seq.)
Prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA. (21 USC § 505 (a))
Under regulation: a) Requires clinical trial sponsors to submit an Investigational New Drug (IND) application to the FDA for clinical investigation of a new drug or new indication of an approved drug, with certain exceptions; b) Requires review and approval from an Institutional Review Board (IRB) before a clinical study can be initiated under an IND; c) Defines an IRB as an appropriately constituted group that has been designated to review and monitor biomedical research involving human subjects, to ensure that a clinical trial is ethical and that the rights of study participants are protected; and, d) Authorizes an IRB to approve, require modifications in, or disapprove research, or to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. (21 Code of Federal Regulations (CFR) Part 312)
Establishes the Office for Human Research Protections (OHRP), which provides leadership in the protection of the rights, welfare, and well-being of subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS). OHRP helps ensure this by providing clarification and guidance, developing educational programs and materials, maintaining regulatory oversight, and providing advice on ethical and regulatory issues in biomedical and social-behavioral research. (45 CFR Part 46)
Existing state law:
Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), administered by the State Department of Public Health (DPH), which regulates the packaging, labeling, and advertising of drugs and devices. (Health and Safety Code (HSC) § 109875 et seq.)
Establishes parameters for the experimental use of drugs, requiring review by a committee for the protection of human subjects, consent by the patient or patient’s parent or guardian, and prohibits a person having an ownership interest in a skilled nursing facility or intermediate care facility from prescribing an experimental drug for a patient in the facility. (HSC §§ 11115 – 111545)
Prohibits, in the Sherman Law, the sale, delivery, or giving away of a new drug or device unless it is either:
A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the FDA, pursuant to federal law, or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated, or suspended under the FDA. (HSC § 111550)
Prohibits a person from manufacturing any drug or device in California unless he or she has a valid license from the DPH. (HSC § 111615)
Authorizes the DPH to require any manufacturer, wholesaler, or importer of any prescription ophthalmic device in California to obtain a license for each place of manufacture. (HSC §§ 111615 and 111620)
Establishes the Protection of Human Subjects in Medical Experimentation Act (PHSME Act) which prescribes various protections for subjects of medical experimentation relating to a bill of rights; informed consent procedures and documentation; and, the provision of specified disclosures, including the right for a subject to give or withdraw consent freely and without duress. Imposes penalties for violations of these protections. (HSC § 24170 et seq.)
States that any person who violates any provision of the Sherman Law, if convicted, is subject to imprisonment for not more than one year in the county jail or a fine of not more than $1,000, or both the imprisonment and fine. States that any person who violates the law by removing, selling, or disposing of an embargoed food, drug, device, or cosmetic without the permission of an authorized agent of the department or court shall, if convicted, be subject to imprisonment for not more than one year in a county jail or a fine of not more than $10,000, or both the fine and imprisonment. States that any person who purchases or sells a foreign dangerous drug or medical device, an illegitimate product, or suspect product, that is not approved or otherwise authorized by the FDA or that is obtained outside of the licensed supply chain regulated by the FDA, California State Board of Pharmacy, or DPH, is guilty of a misdemeanor and subject to imprisonment for not more than one year in a county jail, a fine of not more than $10,000 per occurrence, or both the imprisonment and fine. (HSC §111825)
Requires health plans and insurers to provide an external, independent review process to examine plan's coverage denials of experimental or investigational therapies for individual enrollees who have a life-threatening or seriously debilitating condition and who meet other specified criteria. (HSC § 1370.4)
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an FDA-approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician, recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
(HSC § 1370.6)
Licenses and regulates physicians and surgeons under the Medical Practice Act (MPA) by the Medical Board of California (MBC) within the Department of Consumer Affairs (DCA). (BPC § 2000 et seq.)
Provides that the MBC shall take action against a physician who is charged with unprofessional conduct, as specified. (BPC § 2234)
This
bill:
Enacts the Right to Try Act (Act).
Makes the following definitions:
“Consulting physician” as a physician and surgeon licensed under the MPA or an osteopathic physician and surgeon licensed under the Osteopathic Act who performs examines the qualified individual and his or her relevant medical records, confirms, in writing, the primary physician’s diagnosis and prognosis and verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
“Eligible patient” as a person who has an immediately life-threatening disease or condition; has considered all other treatment options currently approved by the FDA, has been unable to participate in a clinical trial for the immediately life-threatening disease or condition within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process, has received a recommendation from his or her primary physician and a consulting physician for an investigational drug, biological product, or device (IDBPD); has given written informed consent for the use of the IDBPD or his or her legally authorized representative has given written informed consent on their behalf, has documentation from his or her primary physician and a consulting physician that the patient has met these requirements.
“Health benefit plan” as a plan or program that provides, arranges, pays for, or reimburses the cost of health benefits, including but not limited to, a health care service plan contract issued by a health care service plan, and a policy of health insurance issued by a health insurer.
“Immediately life-threatening disease or condition” as a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months.
“Investigational drug, biological product, or device” as a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the FDA but has not been approved for general use by the FDA and remains under investigation in a clinical trial approved by the FDA.
“Primary physician” as a physician and surgeon licensed under the MPA or an osteopathic physician and surgeon licensed under the Osteopathic Act.
“State regulatory board” as the MBC or the Osteopathic Medical Board of California (OMBC).
“Written, informed consent” as a written document that has been approved by the primary physician’s institutional review board or an accredited independent institutional review board, is signed by an eligible patient or their legally authorized representative when the patient lacks the capacity to consent, and attested to by the patient’s primary physician and a witness, that at a minimum, does all of the following:
Explains that the currently approved products and treatments for the immediately life-threatening disease or condition from which the patient suffers.
Attests to the fact that the patient, or when the patient lacks the capacity to consent his or her legally authorized representative, concurs with the patient’s primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’s life.
Clearly identifies the specific proposed IDBPD that the patient is seeking to use.
Describes the potentially best and worst outcomes of using the IDBPD and describes the most likely outcome, including the possibility that new, unanticipated, different, or worse symptoms might result and that death could be hastened by the proposed treatment. Requires the description to be based on the primary physician’s knowledge of the proposed treatment in conjunction with an awareness of the patient’s condition.
Clearly states that the patient’s health benefit plan, if any, and health care provider are not obligated to pay for the IDBPD or any care or treatments consequent to use of the IDBPD.
Clearly states that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements.
Clearly states that in-home health care may be denied if treatment begins.
States that the patient understands that he or she is liable for all expenses consequent to the use of the IDBPD, and that this liability extends to the patient’s estate, except as otherwise provided in the patient’s health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
Clarifies that written consent must be consistent with the informed consent requirements of the PHSME Act.
Authorizes a manufacturer of an IDBPD to make the IDBPD available to an eligible patient pursuant to the Act, but clarifies that a manufacturers is not required to make the IDBPD available to an eligible patient.
Authorizes a manufacturer to provide an IDBPD to an eligible patient without receiving compensation and to require an eligible patient to pay the costs of or associated with the manufacture of the IDBPD.
Prohibits the Act from expanding or otherwise affecting coverage provided by health plans or insurers, the Medi-Cal program, or county organized health systems.
Specifies that the Act does not require a health plan or insurer to provide coverage for the cost of any IDBPD, or the costs of services related to the use of an IDBPD, under the Act, but authorizes a health plan or insurer to provide such coverage.
Prohibits an IDBPD from being offered if a clinical trial for that IDBPD is closed due to the lack of efficacy or for toxicity. Requires the manufacturer and the patient's primary physician, if notice is given of closure of a clinical trial for an IDBPD taken by a patient outside of a clinical trial, to notify the patient of the information from the safety committee of the clinical trial.
Clarifies that the heirs of an eligible patient, if he or she dies while being treated by an IDBPD made available pursuant to the Act, are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
Prohibits a state regulatory board, notwithstanding any other law, from revoking, failing to renew, or taking any other disciplinary action against a physician’s license based solely on the physician’s recommendation to an eligible patient regarding, or prescription for, or treatment with, an IDBPD if the recommendation or prescription is consistent with protocol approved by the physician’s institutional review board or an accredited independent institutional review board.
Requires the physician’s institutional review board or an accredited institutional review board to biannually report information to DPH, MBC and OMBC regarding the number of requests made for an IDBPD; the status of the requests made; the duration of the treatment; the costs of the treatment paid by eligible patients; the success or failure of the IDBPD in treating the immediately life-threatening disease or condition from which the patient suffers and; any adverse event for each IDBPD.
Prohibits a state agency from altering recommendations made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on a recommendation that a patient have access to an IDBPD.
Provides that a violation of the Act shall not be subject to penalties for other violations of provisions of the Sherman Act.
Specifies that the Act does not create a private cause of action, and that actions taken pursuant to the Act do not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an IDBPD, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the IDBPD, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
FISCAL EFFECT: This bill is keyed “fiscal” by Legislative Counsel. According to the Assembly Committee on Appropriations analysis dated May 13, 2015, this bill will result in minor and absorbable costs to DPH, MBC, and OMBC to receive and review biannually reports from institutional review boards on the requests for treatment with an investigational product.
COMMENTS:
Purpose. The Author is the Sponsor of this bill. According to the Author, while the FDA administers a compassionate use program which makes investigational drugs and devices available to terminally ill patients, it often takes months for patients to become approved for participation in the program. The Author states that this bill removes barriers for patients and doctors who believe an investigational drug or device could be their last hope for survival.
Background. According to an April 9, 2015 Health Policy Brief on the issue of right-to-try laws in Health Affairs, under current federal regulations, patients with serious or life-threatening illness have two primary options to access experimental therapies that may treat their condition but that have not yet been approved by the FDA: participate as a human subject in a clinical trial or, for patients who cannot be enrolled in that trial (because of their medical status or geographic location, for example), apply to the FDA for access to the experimental drug under the Expanded Access Program (also known as compassionate use) (EAP).
According to the brief, clinical testing of an experimental drug is typically a three-phase process. Phase I trials are small (20 to 80 patients) and are used primarily to evaluate safety and dosing ranges, usually in healthy volunteers. Phase II trials are larger (typically 100 to 300 patients) and are designed to show early evidence of efficacy in the patients that the drug is intended to treat. Phase III trials may include hundreds or thousands of patients and are used to demonstrate that the drug is effective compared to a control (such as a placebo or a comparator drug). Typically, a manufacturer submits an application to the FDA for marketing approval once a drug has successfully completed Phase III trials. Any drug company wishing to conduct a clinical trial must first submit an IND application to the FDA, which allows the company to manufacture the drug and ship it across state lines for use in the trial. The drug may be only administered to patients who are formally enrolled in that clinical trial. The study population for that trial may be limited based on any number of factors, including specific diagnosis, age, stage of illness, or comorbidities.
The EAP is an attempt at flexibility in the regulatory process and to allow patients with no other treatment options a chance to try therapies they may not otherwise have access to. The program allows patients who meet certain eligibility requirements to receive an experimental therapy outside of the formal clinical research process. An application for expanded access can be submitted by either the drug manufacturer or a licensed physician. There are three categories of expanded access: treatment, single patient, and intermediate, which are further split into two subcategories. One is “expanded access INDs,” through which the manufacturer submits a separate IND for a patient or group of patients, and the other is “expanded access protocols,” whereby the manufacturer amends the protocol under an existing IND to include the patient (or patients) seeking access. Under treatment INDs, a relatively large group of patients (hundreds or thousands) are permitted to access an experimental drug, provided that the sponsor is actively pursuing FDA approval and is in later stages of testing (or has already submitted trial results to the FDA for review).
According to an article published in the January 15, 2015 New England Journal of Medicine, the FDA has permitted almost all expanded access requests regardless of category. The FDA estimated that by 2006, approximately 100,000 patients had obtained expanded access to experimental drugs. Between 2010 and 2013, the FDA imposed clinical holds on only 2 of the 2,472 individual, non-emergency protocols, on 1 of 66 intermediate-size requests, and on none of the 41 widespread expanded-access protocols it received.
The Health Affairs brief states that critics of the EAP have argued that the application process is unnecessarily burdensome and lengthy (it is estimated that the IND application requires about 100 hours to complete), which discourages doctors and manufacturers from applying. An IRB review adds an additional layer of paperwork and potential delay. These requirements were put in place in response to highly publicized incidents of harm caused by unsafe drugs. In the past decade, there have been several attempts made at the federal and judicial levels to further relax restrictions on the administration of experimental therapies to terminally ill patients. One, led by the Abigail Alliance for Better Access to Developmental Drugs, submitted a Citizen Petition to the FDA in 2003 requesting that it make experimental therapies available to terminally ill patients, provided that the drug had passed Phase I testing. Following several years of litigation, the DC Court of Appeals ruled against the Abigail Alliance, stating that terminally ill patients have no constitutional right to access experimental therapies. The US Supreme Court subsequently declined to review the case. Several bills have been introduced in Congress that aim to relax FDA restrictions on access to experimental therapies. The most recent of these (HR 4475, the Compassionate Freedom of Choice Act of 2014) failed to make it out of committee.
In response to criticisms, the FDA recently sought to provide a streamlined alternative for submitting an Investigational New Drug Application (IND) for use in cases of individual patient expanded access and announced it would simplify and accelerate the application process for unapproved investigational drugs that have passed Phase I safety trials. It is estimated that the new application form will take 45 minutes to complete, asks attending physicians to fill in eight pieces of patient information, and requires only one attachment. The FDA issued draft guidance and included a copy of the new form, asking for comment until April 13, 2015 which is available at https://www.federalregister.gov/articles/2015/02/10/2015-02561/individual-patient-expanded-access-applications-form-fda-3926-draft-guidance-for-industry)
Efforts in Other States. Right to try laws are already in place in Arizona, Arkansas, Colorado, Indiana, Louisiana, Michigan, Mississippi, Missouri, Montana, North Dakota, Oklahoma, South Dakota, Utah, Virginia, and Wyoming. Lawmakers in Tennessee have sent a similar bill to their governor for approval. Twenty additional states are considering the law this year. Laws in many states generally allow terminally ill patients to have access to experimental drugs while others also allow health insurers to choose to provide coverage for the cost of these treatments and remove liability for physicians for recommending treatments.
Related Legislation This Year. SB 149 (Stone) is substantively similar to this bill and also enacts the Right to Try Act, permitting a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. (Status: The bill is pending in the Assembly Committee on Health.)
SB 715 (Anderson) is similar to this bill and SB 149 above and permits a manufacturer of a drug, biological product, or device that has not yet received federal or state approval to market to make the product available to eligible patients with terminal illnesses, as specified. (Status: The measure is currently pending in the Senate Committee on Health.)
SB 128 (Wolk) permits a qualified adult with capacity to make medical decisions, who has been diagnosed with a terminal disease to receive a prescription for an aid in dying drug if certain conditions are met. (Status: This bill is pending in the Assembly Committee on Health.)
Arguments in Support. The Amyotrophic Lateral Sclerosis (ALS) Association Golden West Chapter writes in support of this bill, noting that there is no known prevention, cause or cure for ALS and that there is only one FDA-approved drug available to manage ALS symptoms which is known to extend life by a few months.
According to the Los Angeles County Board of Supervisors, seriously ill patients who have exhausted their options to find a cure and who have identified physicians and a pharmaceutical company willing to assist them, deserve the right to experimental treatments that could improve their health conditions or prolong their lives.
Concerns. The Pharmaceutical Research and Manufacturers of America (PhRMA) writes with concerns about this bill, stating that it could have serious unintended consequences that must be taken into consideration. According to PhRMA, the bill may be premature, the FDA already operates the EAP through which patients are able to access investigational drugs in the early stages of clinical development, the FDA has announced plans to streamline the program and it may be prudent for the Legislature to hold off on passing this bill in order to allow the federal process to continue.
Arguments in Opposition. The Association of Northern California Oncologists is opposed to this bill for several reasons, including the difficulty of identifying terminally ill patients, the danger a right to try outside the context of a clinical trial would present to clinical trial enrollment and the lack of appropriate physician supervision of the use of these drugs. According to the group, any threat to adult clinical trial enrollment would result in slowing the development of cancer care in the future.
According to the California Nurses Association and National Nurses United, this bill promises vulnerable patients and their families that there will be a state program for obtaining drugs that is similar to the FDA EAP only shorter, the bill does not address the real barriers to compassionate use and nothing in this bill impacts the availability of drugs to terminally ill patients unless the manufacturers of the drugs allow it to be used in advance of FDA approval. The organizations state that the only right that is being promoted in this legislation is the right of wealthy individuals who can afford to fund the process and associated costs to access those drugs that pharmaceutical companies in their infinite greed and focused self-interest are willing to make available.
SUPPORT AND OPPOSITION:
Support:
Amyotrophic Lateral Sclerosis (ALS) Association Golden West Chapter
Los Angeles County Board of Supervisors
Concerns:
Pharmaceutical Research and Manufacturers of America (PhRMA)
Opposition:
Association of Northern California Oncologists
California Nurses Association and National Nurses United
-- END --
AB 159 (Calderon) Page 9 of 9
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: AB 159
AUTHOR: |
Calderon |
||
VERSION: |
June 1, 2015 |
||
HEARING DATE: |
June 10, 2015 |
|
|
CONSULTANT: |
Melanie Moreno |
||
SUBJECT: Investigational drugs, biological products, and devices.
SUMMARY:
Permits a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. Prohibits this bill from requiring that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
Existing state law:
Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), which regulates the packaging, labeling, and advertising of drugs and devices, administered by the Department of Public Health (DPH).
Prohibits, in the Sherman Law, the sale, delivery, or giving away of a new drug or device unless it is either:
A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the U.S. Food and Drug Administration (FDA), pursuant to federal law, or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated, or suspended under the FDA.
Establishes the Protection of Human Subjects in Medical Experimentation Act which prescribes various protections for subjects of medical experimentation relating to a bill of rights; informed consent procedures and documentation; and, the provision of specified disclosures, including the right for a subject to give or withdraw consent freely and without duress. Imposes penalties for violations of these protections.
Requires health plans and insurers to provide an external, independent review process to examine plan’s coverage denials of experimental or investigational therapies for individual enrollees who have a life-threatening or seriously debilitating condition and who meet other specified criteria.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an FDA-approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician, recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
Existing federal law:
Establishes the federal Food, Drug, and Cosmetic Act, which grants authority to the FDA to oversee the safety of food, drugs, and cosmetics.
Prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
Under regulation: a) Requires clinical trial sponsors to submit an Investigational New Drug (IND) application to the FDA for clinical investigation of a new drug or new indication of an approved drug, with certain exceptions; b) Requires review and approval from an Institutional Review Board (IRB) before a clinical study can be initiated under an IND; c) Defines an IRB as an appropriately constituted group that has been designated to review and monitor biomedical research involving human subjects, to ensure that a clinical trial is ethical and that the rights of study participants are protected; and, d) Authorizes an IRB to approve, require modifications in, or disapprove research, or to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects.
Establishes the Office for Human Research Protections (OHRP), which provides leadership in the protection of the rights, welfare, and well-being of subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS). OHRP helps ensure this by providing clarification and guidance, developing educational programs and materials, maintaining regulatory oversight, and providing advice on ethical and regulatory issues in biomedical and social-behavioral research.
This bill:
Permits a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. Prohibits this bill from requiring that a manufacturer make available an investigational drug, biological product, or device to an eligible patient.
Defines “investigational drug, biological product, or device” as a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the FDA, but has not been approved for general use by the USDA and remains under investigation in a clinical trial approved by the FDA.
Defines “eligible patient” as a person who:
Has a serious or immediately life-threatening disease or condition. Defines “immediately life-threatening disease or condition” as a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment;
Has considered all other treatment options currently approved by the FDA;
Has been unable to participate in a clinical trial for the serious or immediately life-threatening disease or condition within 100 miles of his or her home or has not been accepted to that clinical trial within one week of completion of the clinical trial application process; and,
Has received a recommendation from his or her primary physician and a consulting physician, as defined, for an investigational drug, biological product, or device. Defines “consulting physician” as a physician and surgeon or an osteopathic physician and surgeon who:
Examines the qualified individual and his or her relevant medical records;
Confirms, in writing, the primary physician’s diagnosis and prognosis; and,
Verifies, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
Has given written informed consent for the use of the investigational drug, biological product, or device, or, if he or she lacks the capacity to consent, his or her legally authorized representative has given written informed consent on his or her behalf. Defines “written informed consent” as a written document that has been approved by the primary physician’s IRB or an accredited independent IRB, is signed by an eligible patient, or his or her legally authorized representative when the patient lacks the capacity to consent, and attested to by the patient’s primary physician and a witness that, at a minimum:
Explains the currently approved products and treatments for the disease or condition from which the patient suffers;
Attests to the fact that the patient, or his or her legally authorized representative, concurs with the primary physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’s life;
Clearly identifies the specific proposed investigational drug, biological product, or device that the patient is seeking to use;
Describes the potentially best and worst outcomes of using the investigational drug, biological product, or device and describes the most likely outcome, as specified;
Clearly states that the patient’s health plan or insurer, if any, and health care provider are not obligated to pay for the investigational drug, biological product, or device or any care or treatments consequent to use of the investigational drug, biological product, or device;
Clearly states that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements;
Clearly states that in-home health care may be denied if treatment begins; and,
States that the patient understands that he or she is liable for all expenses consequent to the use of the investigational drug, biological product, or device, and that this liability extends to the patient’s estate, except as otherwise provided in the patient’s health benefit plan or a contract between the patient and the manufacturer of the drug, biological product, or device.
Permits a manufacturer to provide an investigational drug, biological product, or device to an eligible patient without receiving compensation and to require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.
Prohibits this bill from expanding or otherwise affecting coverage provided by health plans or insurers, the Medi-Cal program, or county organized health systems.
Specifies that this bill does not require a health plan or insurer to provide coverage for the cost of any investigational drug, biological product, or device, or the costs of services related to the use of an investigational drug, biological product, or device under this bill, but permits one to provide such coverage.
Prohibits an investigational drug, biological product, or device from being offered if a clinical trial for that investigational drug, biological product, or device is closed due to the lack of efficacy or for toxicity. Requires the manufacturer and the patient’s primary physician, if notice is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, to notify the patient of the information from the safety committee of the clinical trial.
Prohibits the heirs of an eligible patient, if he/she dies while being treated by an investigational drug, biological product, or device made available pursuant to this bill, from being liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
Prohibits a state regulatory board from revoking, failing to renew, or taking any other disciplinary action against a physician’s license based solely on the physician’s recommendation to an eligible patient regarding, or prescription for or treatment with, an investigational drug, biological product, or device if the recommendation or prescription is consistent with protocol approved by the physician’s IRB or an accredited independent institutional review board.
Requires the physician’s IRB or an accredited institutional review board to biannually report to DPH, the Medical Board of California (MBC), and the Osteopathic Medical Board of California (OMBC):
The number of requests made for an investigational drug, biological product, or device;
The status of the requests made;
The duration of the treatment; and,
The costs of the treatment paid by eligible patients.
Prohibits a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to an investigational drug, biological product, or device.
Prohibits an official, employee, or agent of this state from blocking or attempting to block an eligible patient’s access to an investigational drug, biological product, or device pursuant to this bill, except for counseling, advice, or a recommendation consistent with medical standards of care from a licensed healthcare provider.
Makes a violation of this bill not subject to the Sherman Law.
Specifies that this bill does not create a private cause of action, and that actions taken pursuant to this bill do not serve as a basis for a civil, criminal, or disciplinary claim or cause of action, including, but not limited to, product liability, medical negligence, or wrongful death, against a manufacturer of an investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient for harm done to the eligible patient or his or her heirs resulting from the investigational drug, biological product, or device, or the use or nonuse thereof, if the manufacturer or other person or entity has complied with the terms of this article in relation to the eligible patient, unless there was a failure to exercise reasonable care.
FISCAL EFFECT:
According to the Assembly Appropriations Committee analysis, minor and absorbable costs to DPH, the MBC, and OMBC to receive and review biannually reports from institutional review boards on the requests for treatment with an investigational product.
PRIOR VOTES:
Assembly Floor: |
74 - 2 |
Assembly Appropriations Committee: |
15 - 0 |
Assembly Health Committee: |
17 - 0 |
COMMENTS:
Author’s statement. According to the author, terminally ill patients often do not have the luxury of waiting for the FDA to grant compassionate use or participating in the lengthy process of clinical trials. AB 159 gives terminally ill patients a chance to try potentially life-saving treatments after all other options have been exhausted. It removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
Background. According to an April 9, 2015 Health Policy Brief on the issue of right-to-try laws in Health Affairs, under current federal regulations, patients with serious or life-threatening illness have two primary options to access experimental therapies that may treat their condition but that have not yet been approved by the FDA: participate as a human subject in a clinical trial or, for patients who cannot be enrolled in that trial (because of their medical status or geographic location, for example), apply to the FDA for access to the experimental drug under the expanded access (also known as compassionate use) program.
Clinical trials. According to the Health Affairs brief, clinical testing of an experimental drug is typically a three-phase process. Phase I trials are small (20 to 80 patients) and are used primarily to evaluate safety and dosing ranges, usually in healthy volunteers. Phase II trials are larger (typically 100 to 300 patients) and are designed to show early evidence of efficacy in the patients that the drug is intended to treat. Phase III trials may include hundreds or thousands of patients and are used to demonstrate that the drug is effective compared to a control (such as a placebo or a comparator drug). Typically, a manufacturer submits an application to the FDA for marketing approval once a drug has successfully completed Phase III trials. Any drug company wishing to conduct a clinical trial must first submit an IND application to the FDA, which allows the company to manufacture the drug and ship it across state lines for use in the trial. The drug may be only administered to patients who are formally enrolled in that clinical trial. The study population for that trial may be limited based on any number of factors, including specific diagnosis, age, stage of illness, or comorbidities.
Expanded access program. According to the Health Affairs brief, the expanded access program is an attempt at flexibility in the regulatory process and to allow patients with no other treatment options a chance to try therapies they may not otherwise have access to. The program allows patients who meet certain eligibility requirements to receive an experimental therapy outside of the formal clinical research process. An application for expanded access can be submitted by either the drug manufacturer or a licensed physician. There are three categories of expanded access: treatment, single patient, and intermediate, which are further split into two subcategories. One is “expanded access INDs,” through which the manufacturer submits a separate IND for a patient or group of patients, and the other is “expanded access protocols,” whereby the manufacturer amends the protocol under an existing IND to include the patient (or patients) seeking access. Under treatment INDs, a relatively large group of patients (hundreds or thousands) are permitted to access an experimental drug, provided that the sponsor is actively pursuing FDA approval and is in later stages of testing (or has already submitted trial results to the FDA for review). According to an article published in the January 15, 2015 New England Journal of Medicine (NEJM), the FDA has permitted almost all expanded access requests regardless of category. The FDA estimated that by 2006, approximately 100,000 patients had obtained expanded access to experimental drugs. Between 2010 and 2013, the FDA imposed clinical holds on only 2 of the 2,472 individual, non-emergency protocols, on 1 of 66 intermediate-size requests, and on none of the 41 widespread expanded-access protocols it received.
The Health Affairs brief states that critics of the expanded access program have argued that the application process is unnecessarily burdensome and lengthy (it is estimated that the IND application requires about 100 hours to complete), which discourages doctors and manufacturers from applying. An IRB review adds an additional layer of paperwork and potential delay. These requirements were put in place in response to highly publicized incidents of harm caused by unsafe drugs. In the past decade, there have been several attempts made at the federal and judicial levels to further relax restrictions on the administration of experimental therapies to terminally ill patients. One, led by the Abigail Alliance for Better Access to Developmental Drugs, submitted a Citizen Petition to the FDA in 2003 requesting that it make experimental therapies available to terminally ill patients, provided that the drug had passed Phase I testing. Following several years of litigation, the DC Court of Appeals ruled against the Abigail Alliance, stating that terminally ill patients have no constitutional right to access experimental therapies. The US Supreme Court subsequently declined to review the case. Several bills have been introduced in the US Congress that aim to relax FDA restrictions on access to experimental therapies. The most recent of these (HR 4475, the Compassionate Freedom of Choice Act of 2014) failed to make it out of committee.
Other states. Over the past year, the issue of access to experimental therapies has been debated at the state level, in part due to efforts of the Goldwater Institute, a libertarian think tank that appears to be the source of this bill. In February 2014, the Institute released a policy paper that outlines the major critiques of the FDA’s expanded access program and proposes model legislation for states to adopt. According to the National Conference of State Legislatures (NCSL), legislation related to right-to-try have been introduced in 30 states. Arizona, Colorado, Louisiana, Michigan, and Missouri have laws on the subject.
FDA action. According to an article in the Wall Street Journal published on February 9, 2015, the FDA announced it would “simplify and accelerate” the application process for “unapproved investigational drugs” that have passed Phase I safety trials. It is estimated that the new application form will take 45 minutes to complete, asks attending physicians to fill in eight pieces of patient information, and requires only one attachment. The FDA issued draft guidance and included a copy of the new form, asking for comment until April 13, 2015. The FDA is now in the process of reviewing the public comments and will not likely finalize the guidance before late summer/early fall.
NEJM article. The authors of the January 2015 NEJM article mentioned above call right-to-try laws misguided, and call for a more pragmatic approach. They suggest that states work collaboratively with the FDA to make expanded access more practical when it is appropriate. For example, since the FDA has acknowledged that gaining approval from an IRB can pose a barrier, states could partner with the FDA to fund multicenter IRBs that focus specifically on expanded-access requests. Such multicenter panels would conduct full reviews, but their subject-matter expertise and limited dockets would translate into faster review times. Practical obstacles to enhancing expanded access programs, including administrative burdens and industry costs, would also be best tackled by the states in partnership with the FDA. For example, a manufacturer’s reluctance to provide product because of financial concerns could be addressed by permitting companies to charge amounts closer to the likely post approval cost of drugs.
Double referral. This bill is double referred. Should it pass out of this committee, it will be referred to the Senate Committee on Business and Professions and Economic Development.
Related legislation. SB 149 (Stone) is substantially similar to this bill, and enacts the Right to Try Act, permitting a manufacturer of an investigational drug, biological product, or device to make available an investigational drug, biological product, or device to an eligible patient, as defined. SB 149 is pending in the Assembly.
SB 715 (Anderson), permits a manufacturer of a drug, biological product, or device that has not yet received federal or state approval to market to make the product available to eligible patients with terminal illnesses, as specified. SB 715 was set for hearing in this Committee, but withdrawn at the request of the author.
SB 128 (Wolk and Monning), would permit a qualified adult with capacity to make medical decisions, who has been diagnosed with a terminal disease to receive a prescription for an aid in dying drug if certain conditions are met, such as two oral requests, a minimum of 15 days apart and a signed written request witnessed by two individuals is provided to his or her attending physician, the attending physician refers the patient to an independent, consulting physician to confirm diagnosis and capacity of the patient to make medical decisions, and the attending physician refers the patient for a mental health specialist assessment if there are indications of a mental disorder. SB 128 is pending in the Assembly.
Support. The Los Angeles County Board of Supervisors states that seriously ill patients, who have exhausted their options to find a cure and who have identified physicians and a pharmaceutical company willing to assist them, deserve the right to experimental treatments that could improve their health conditions for prolonging their lives. The ALS Association Golden West Chapter states that they support and advocate for expanded access to experimental treatments for people living with ALS.
Opposition. The Association of Northern California Oncologists cite the difficulty of identifying a terminally-ill patient, the danger a “right to try” policy outside the context of a clinical trial would present to adult clinical trial enrollment and the lack of an informed consent process to protect patients seeking investigational drugs as reasons for establishing their oppose position on the bill. The California Nurses Association/National Nurses United (CNA) maintain that this bill does nothing to address the real barriers to “compassionate use” revealed in a recent article in the NEJM entitled Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs, specifically stating that nothing in this legislation impacts the availability of drugs to terminally ill patients unless the manufacturer of the drugs allow it to be used in advance of FDA approval. The CNA goes on to state instead of taking on the cost of drugs and challenging drug manufacturers that charge excessive prices for all drugs sold in California, this bill reinforces the status quo for investigational drug costs.
Concerns. The Pharmaceutical Research and Manufacturers of America (PhRMA) that that this bill may be premature given recent developments at the federal level with the FDA’s recent announcement of plans to streamline the expanded access program. PhRMA further states that the key to both clinical trials and the expanded access program is that patients are given investigational drugs in controlled circumstances and under the close supervision of a physician and other health care providers. PhRMA states that allowing patients a blanket “right to try” would allow them access to these drugs outside monitored settings with perhaps catastrophic results for patients.
Policy comments.
Definition of “terminal disease” vs. “immediately life-threatening disease or condition.” This bill requires an eligible patient, in order to receive an investigational drug, biological product, or device, have an immediately life-threatening disease or condition (“a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment), consistent with FDA regulations related to expanded access. At the request of this Committee, SB 149 was amended to require an eligible patient have a terminal disease (“an incurable and irreversible disease that has been medically confirmed and will, according to reasonable medical judgment, result in death within six months of diagnosis”) consistent with existing California statute and the Oregon death with dignity statute. Additionally, this bill defines the term “serious disease or condition” to mean “a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning,” however that phrase does not appear in any other place in the bill. The Committee may wish to amend this bill to include definitions consistent with those contained in SB 149.
Data collection. This bill requires some data to be reported to DPH, MBC, and OMB, similar to the data that this Committee requested be reported under SB 149 but included two more data elements. To be consistent, the Committee may wish to amend this bill to add:
The success or failure of the investigational drug, biological product, or device in treating the terminal disease with which the eligible patient was diagnosed.
Any adverse event for each investigational drug, biological product, or device.
“Blocking access” provision. This bill prohibits “an official, employee, or agent of this state” from “block(ing) or attempt(ing) to block an eligible patient’s access to an investigational drug, biological product, or device.” It is unclear whether or not this could be construed to mean that if Medi-Cal doesn’t cover drugs or devices under this bill, that would be considered blocking a patient’s access. The author’s office states that this provision was modeled on Colorado’s statute, and was not intended to include coverage decisions or other payment factors as “blocking” access. The Committee may wish to consider amending this provision to clarify this provision is consistent with the author’s intent, and to ensure that it does not affect what is covered by state health insurance programs.
Informed consent provisions. This bill contains detailed language on what is required to be contained in the form that a patient would sign in order give his or her written, informed consent. In at least two places, there is inconsistency between what is stated in required to be stated under the form and the provisions of the bill. This bill should be amended to fix those inconsistencies.
Technical and clarifying amendments.
On page 6, line 16:
This article does not expand or
otherwise affect
the coverage provided under Sections 1370.4 and 1370.6 of this code,
Sections 10145.3 and 10145.4 of the Insurance Code, or Sections
14087.11 and 14132.98 of the Welfare and Institutions Code.
On page 6, on line 30:
If notice of a closure of a clinical trial is given for an investigational drug, biological product, or device taken by a patient outside of a clinical trial, the manufacturer and the patient’s primary physician shall notify the patient of the information from the safety committee of the clinical trial.
SUPPORT AND OPPOSITION:
Support: ALS Association Golden West Chapter
Los Angeles County Board of Supervisors
Oppose: Association of Northern California Oncologists
California Nurses Association
California Right to Life Committee, Inc.
-- END --
AB 159
Page 3
ASSEMBLY THIRD READING
AB 159
(Calderon)
As Amended April 28, 2015
Majority vote
Committee |
Votes |
Ayes |
Noes |
Health |
17-0 |
Bonta, Maienschein, Burke, Chiu, Gomez, Gonzalez, Roger Hernández, Lackey, Nazarian, Patterson, Ridley-Thomas, Rodriguez, Santiago, Steinorth, Thurmond, Waldron, Wood |
|
Business & Professions |
14-0 |
Bonilla, Jones, Baker, Bloom, Campos, Chang, Dodd, Eggman, Gatto, Holden, Mullin, Ting, Wilk, Wood |
|
Appropriations |
15-0 |
Gomez, Bigelow, Bloom, Bonta, Calderon, Chang, Daly, Eggman, Eduardo Garcia, Holden, Jones, Rendon, Wagner, Weber, Wood |
|
SUMMARY: Permits a manufacturer of a drug, biological product, or device (experimental drug or device) that has not yet received federal or state approval to market to make the product available to eligible patients with serious or immediately life-threatening diseases, as specified.
EXISTING STATE LAW:
Prohibits, under the Sherman Food, Drug, and Cosmetic Law, the sale, delivery, or giving away of a new drug or device unless it is either
A new drug or new device for which the California Department of Public Health (DPH) has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the United States Food and Drug Administration (FDA).
EXISTING FEDERAL LAW: Prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
FISCAL EFFECT: According to the Assembly Appropriations Committee, minor and absorbable costs to DPH, the Medical Board of California, and the Osteopathic Medical Board of California to receive and review biannually reports from institutional review boards on the requests for treatment with an investigational product.
COMMENTS: According to the author, this bill removes barriers to accessing potentially life-saving drugs for terminally-ill patients and doctors who believe an investigational drug or device could be their last hope for survival. These patients may seek compassionate use exemptions from the FDA, but the process is cumbersome and approval comes too late for many. This bill removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
Background. A clinical trial is a study that is carefully designed to test the benefits and risks of a specific medical treatment or intervention, such as a new drug. The FDA requires a multi-phase clinical trials process to be completed before deciding if an investigational medicine is safe and effective for a broader patient population. Experimental drugs and devices go through clinical trials, stage one of which establishes very basic safety level and assesses toxicity. Once a drug or device passes stage one, there are two more phases before being approved for sale. This bill would allow manufacturers to make available investigational products, that have passed phase one trials, to patients meeting specified criteria, and would protect from liability doctors who recommend or prescribe the investigational products, as well as manufacturers who make them available.
Expanded Access to investigational products through the FDA. Patients who are not eligible for a clinical trial because of where they live, their age, or some other disqualifying factor have the option to seek expanded access if they have serious or life-threatening conditions and no comparable or satisfactory alternative is available. The FDA has in place processes to allow patients access: expanded access, which is sometimes called "compassionate use," supplements the clinical trials process. A licensed physician is able to apply for expanded access on behalf of the patient. The FDA states that they receive approximately 1,000 expanded use applications per year, and has approved more than 99% of those applications. In the last four years, the FDA has denied only 33 of nearly 6,000 expanded access requests. Emergency requests are often granted immediately over the phone. For non-emergencies, the FDA states that they strive to respond promptly and, in general, approve the request within 30 days.
Critics of the FDA process have raised concerns that the expanded access application is too cumbersome for physicians and patients to complete. Critics claim that it currently requires an application that takes doctors 100 hours to fill out. On February 4, 2015, the FDA announced that it would be streamlining the expanded use application process, and stated that the proposed application will allow physicians to apply for experimental drugs in just 45 minutes. The FDA draft guidance on the new application process is currently in the public comment period and the new final rule should be released shortly.
Court History. In 2005, the Abigail Alliance for Better Access to Developmental Drugs, with the mission of facilitating access to experimental drugs for patients, sued the FDA, claiming a constitutional due process right for terminally ill patients to access unapproved drugs. A United States District court disagreed and the case was heard by the United States Court of Appeals for the District of Columbia Circuit. In 2006, a divided three-judge panel of the District of Columbia Circuit agreed with the Alliance, finding that where there are no other FDA-approved treatment options, a terminally ill patient has a constitutionally-protected "fundamental right" to access investigational drugs. In 2007, the District of Columbia Circuit reheard the case "en banc" and reversed the panel decision. The Alliance then filed a petition asking the United States Supreme Court to hear the case but the Supreme Court denied the petition, so for now the Court of Appeals decision stands.
Support. The Los Angeles County Board of Supervisors supports this bill.
Opposition. The California Medical Association, California Nurse Association/National Nurses United (CNA), Association of Northern California Oncologists oppose this bill, citing patient safety and other concerns. The Association of Northern California Oncologists believe this bill threatens the viability of adult clinical trial enrollment and would result in slowing the development of cancer care in the future. CNA points out that "nothing in this legislation impacts the availability of drugs to terminally ill patients unless the manufacturers of the drugs allow it to be used in advance of FDA approval". If a manufacturer provided an experimental drug or device to a patient without FDA approval under this law, they would be in violation for federal law.
Statement of Concern. The Pharmaceutical Research and Manufacturers Association (PhRMA) filed a letter of concern with this Committee, stating that Right-to-Try legislation, while well-intentioned, could have serious unintended consequences that must be taken into consideration. Robust clinical trials are one of the key elements in bringing new therapies to market. PhRMA states that it is imperative that investigational drugs be used within the boundaries of carefully constructed and monitored clinical trials to ensure patient safety, and to glean key understandings about the safety, efficacy, and uses of investigational drugs. Furthermore, PhRMA is concerned with the lack of oversight and accountability in this legislation. Both clinical trials and the FDA's expanded access program require that patients be given these under the close supervisions of a physician and other health care providers to closely monitor patient reactions. Allowing blanket access to these drugs outside of monitored trials could yield catastrophic results for the patient.
Analysis Prepared by: Dharia McGrew / HEALTH / (916) 319-2097 FN: 0000390
AB 159
Page 3
Date of Hearing: May 13, 2015
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Jimmy Gomez, Chair
AB 159
(Calderon) – As Amended April 28, 2015
Policy Committee: |
Health |
Vote: |
17 - 0 |
|
Business and Professions |
|
14 - 0 |
|
|
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill sets up a legal structure whereby individuals with serious or immediately life-threatening conditions can gain access to investigational drugs, biological product, or medical devices (investigational products). Specifically, this bill:
Defines investigational drug, biological product, or device as a drug, biological product, or device that has successfully completed phase one of a clinical trial approved by the United States Food and Drug Administration (FDA), but has not been approved for general use and remains under investigation in an approved clinical trial.
Allows, but does not require, the manufacturer of an investigational product to make the product available to an eligible patient, as defined. Specifies that the manufacturer require a patient to pay for the costs of the investigational product.
Defines an eligible patient as one who has met a number of specified criteria, including having a serious or life-threatening condition, as defined, and having considered all FDA-approved treatment options.
Allows, but does not require, a health plan or insurer to provide coverage for the investigational product, or the costs of services related to the use of the investigational product.
Prohibits a state regulatory board from taking disciplinary action against a physician's license, and prohibits a state agency from altering a recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program, based on the recommendation, prescription, or treatment of the investigational product, provided the recommendation or prescription is consistent with protocol approved by an institutional review board.
Prohibits an official, employee, or agent of the state from blocking or attempting to block an eligible patient’s access to an investigational product pursuant to this article.
Specifies it does not create a private cause of action against a manufacturer of an investigational product, or against any other person or entity involved in the care of an eligible patient using the investigational product, for any harm done to the patient resulting from it, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
Requires institutional review boards to report information about requests for investigational products to the California Department of Public Health (CDPH), the Medical Board of California (MBC), and the Osteopathic Medical Board of California (OBMC).
FISCAL EFFECT:
Minor and absorbable costs to CDPH, MBC, and OMBC to receive and review biannually reports from institutional review boards on the requests for treatment with an investigational product.
COMMENTS:
Purpose. According to the author, this bill removes barriers to accessing potentially life-saving drugs for terminally-ill patients and doctors who believe an investigational drug or device could be their last hope for survival. These patients may seek compassionate use exemptions from the FDA, but the process is cumbersome and approval comes too late for many. This bill removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
Background. Drugs and devices go through clinical trials, stage one of which establishes safety and assesses toxicity. Once a drug or devices passes stage one, there are two more phases before being approved for sale. This bill would allow manufacturers to make available investigational products, that have passed phase one trials, to patients meeting specified criteria, and would protect from liability doctors who recommend or prescribe the investigational products, as well as manufacturers who make them available.
Experimental treatments are often available by participating in a
clinical trial. If a patient is unable to enroll in a clinical
trial, the FDA expanded access exemption, also called “compassionate
use,” provides a pathway for patients to gain access to
investigational drugs or devices for serious diseases or conditions.
A licensed physician is able to apply for expanded access on behalf
of the patient. The physician must be willing to commit to oversee
the treatment, work with the manufacturing company and FDA, obtain
the drugs, monitor the patient during the course of treatment, and
file necessary paperwork. The FDA states that they receive
approximately 1,000 expanded use applications per year, and has
approved more than 99% of those applications.
Support. The Los Angeles County Board of Supervisors supports this bill.
Opposition. The California Medical Association, California Nurse Association/National Nurses United, Association of Northern California Oncologists oppose this bill, citing patient safety and other concerns. The Association of Northern California Oncologists believe this bill threatens the viability of adult clinical trial enrollment and would result in slowing the development of cancer care in the future.
Related Legislation.
SB 149 (Stone), pending in Senate Appropriations Committee, is largely similar to this bill, with differences primarily in definitions and liability exemptions.
SB 715 (Anderson) is largely the same as this bill with some differences in definitions. SB 715 was referred to Senate Health Committee and not heard.
SB 128 (Wolk), pending in the Senate Appropriations Committee, permits a competent, qualified individual who is a terminally ill adult to receive a prescription for aid in dying medication if certain conditions are met.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
AB 159
Page 9
Date of Hearing: April 21, 2015
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Susan Bonilla, Chair
AB 159
Calderon – As Amended April 13, 2015
NOTE: This bill is double referred, having been previously heard by the Assembly Committee on Health on April 14, 2015 and approved on a 17-0 vote.
SUBJECT: Investigational drugs, biological products, and devices.
SUMMARY: Permits a manufacturer of an investigational drug, biological product or device to make the product available to eligible patients, with a serious or immediately life-threatening disease or condition, and authorizes a health benefit plan to provide coverage; prohibits the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against a licensee based solely on the physician’s recommendation, prescription of a biological product or device or treatment of a patient with such products or devices; prohibits a state agency from altering any recommendation made to the federal Centers for Medicare and Medicaid Services regarding a provider’s certification to participate in the programs based solely on the recommendation that a patient have access to a drug, product or device; and, prohibits an official, employee or agent of the state from blocking an eligible patient’s access to the drug, product or device.
EXISTING LAW:
The Business and Professions Code
Establishes the Medical Board of California (MBC), within the Department of Consumer Affairs (DCA), which provides for the licensure and regulation of physicians and surgeons, and requires the MBC to take action against a licensee who is charged with unprofessional conduct. (Business and Professions Code (BPC) § 2000 et seq.)
Provides for the licensure and regulation of osteopathic physicians and surgeons by the MBC within the DCA and requires the OMB to enforce the Medical Practice Act. (BPC § 2000 et seq.)
The Health and Safety Code
Establishes the Sherman Food, Drug, and Cosmetic Law, which regulates the packaging, labeling, and advertising of drugs and devices, administered by the Department of Public Health (DPH).
Prohibits, in the Sherman Law, the sale, delivery or giving away of a new drug or device unless it is either:
A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the U.S. Food and Drug Administration (FDA), pursuant to federal law or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated or suspended under the FDA.
Establishes the Protection of Human Subjects in Medical Experimentation Act which prescribes various protections for subjects of medical experimentation relating to a bill of rights; informed consent procedures and documentation; and, the provision of specified disclosures, including the right for a subject to give or withdraw consent freely and without duress. Imposes penalties for violations of these protections.
Requires health plans and insurers to provide an external, independent review process to examine plan’s coverage denials of experimental or investigational therapies for individual enrollees who have a life-threatening or seriously debilitating condition and who meet other specified criteria.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an FDA-approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician, recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
Federal Law
Establishes the federal Food, Drug, and Cosmetic Act, which grants authority to the FDA to oversee the safety of food, drugs, and cosmetics.
Prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
Under federal regulation:
Requires clinical trial sponsors to submit an Investigational New Drug (IND) application to the FDA for clinical investigation of a new drug or new indication of an approved drug, with certain exceptions;
Requires review and approval from an Institutional Review Board (IRB) before a clinical study can be initiated under an IND;
Defines an IRB as an appropriately constituted group that has been designated to review and monitor biomedical research involving human subjects, to ensure that a clinical trial is ethical and that the rights of study participants are protected; and,
Authorizes an IRB to approve, require modifications in, or disapprove research, or to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects.
Establishes the Office for Human Research Protections (OHRP), which provides leadership in the protection of the rights, welfare and wellbeing of subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS).
THIS BILL:
Allows the manufacturer of an experimental drug or device to provide an investigational drug or device to an eligible patient.
Specifies that the manufacturer may provide for free, or may charge the patient to pay for the costs of the drug or device.
Defines “eligible patient” as one who has met all the following criteria:
Has a serious or immediately life-threatening disease or condition;
Has considered all other treatment options currently approved by the FDA;
Has been unable to participate in a clinical trial within 100 miles of their home, or has not been accepted;
Has received recommendation from their physician for the drug or device;
Has given written, informed consent; and,
Has documentation form their physician attesting that the patient has met these requirements.
Defines “health benefit plan” as any plan or program that provides, arranges, pays for or reimburses the cost of health benefits and includes, but is not limited to, a health care service plan contract issued by a health care service plan and a policy of health insurance issued by a health insurer.
Defines “immediately life threatening disease or condition” to mean a stage of disease in which there is a reasonable likelihood that death will occur within a matter of months or in which premature death is likely without early treatment.
Defines “serious disease or condition” to mean a disease or condition associated with morbidity that has a substantial impact on day-to-day functioning.
Defines “investigational drug, biological product or device” as a drug, biological product or device that has successfully completed phase one of a clinical trial approved by the U.S. FDA, but has not been approved for general use by the FDA and remains under investigation in a clinical trial approved by the FDA.
Defines “physician” as a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act.
Defines “state regulatory board” as the MBC and the OMB.
Defines “written, informed consent” as a written document that has been approved by the physician’s IRB or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative where the patient lacks the capacity to consent, and attested to by the patient’s physician and a witness that, at a minimum, does all of the following:
Explains the currently approved products and treatments for the serious or immediately life-threatening disease or condition from which the patient suffers;
Attests to the fact that the patient, or where the patient lacks the capacity to consent, his or her legally authorized representative, concurs with the patient’s physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’s life;
Clearly identifies the specific proposed investigational drug, biological product or device that the patient is seeking to use;
Describes the potentially best and worst outcomes of using the investigational drug, biological product or device and describes the most likely outcome;
States that the patient’s health benefit plan and health care provider are not obligated to pay for the investigational drug, biological product or device or any care or treatments consequent to use of the them;
States that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment and that care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements;
States that in-home health care may be denied if treatment begins; and,
States that the patient understands and is liable for all expenses consequent to the use of the investigational drug, biological product or device.
Allows a health plan to provide coverage for the drug or device, or the costs of services related to the use of the drug or device.
Prohibits a state regulatory board form revoking, failing to renew, or taking any other disciplinary action against a physician's license based on the recommendation, prescription, or treatment of the drug or device, provided the recommendation or prescription is consistent with the medical standards of care.
Indicates that written, informed consent shall be consistent with the informed consent requirements of the Protection of Human Subjects in Medical Experimentation Act.
Specifics that health benefit plans are not required to provide coverage for the cost or use of any investigational drug, biological product or device or the costs of services.
States that if an eligible patient dies while being treated by an investigational drug, biological product of device made available pursuant to this article, the patient’s heirs are not liable for any outstanding debt related to the treatment or lack of insurance for the treatment.
Prohibits a state agency from altering a recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to the drug or device.
Prohibits an official, employee, or agent of the state from blocking or attempting to block an eligible patient’s access to an investigational drug or device pursuant to this article. Specifies that counseling, advice, or a recommendation consistent with medical standards of care from a licensed healthcare provider is not a violation of this section.
Specifies that this article does not create a private cause of action against a manufacturer of an investigational drug or device, or against any other person or entity involved in the care of an eligible patient using the drug or device, for any harm done to the patient resulting from the drug or device, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author, “Terminally ill patients often do not have the luxury of waiting for the FDA to grant compassionate use of participating in the lengthy process of clinical trials. AB 159 gives terminally ill patients a chance to try potentially life-saving treatments after all other options have been exhausted. It removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.”
Background. The FDA has jurisdiction over all drugs that are sold across state lines. State law provides DPH with the authority to approve for market a drug or device that is sold in California. If a product has received the FDA approval, then the DPH automatically recognizes the product's approval. In rare instances when a drug or device will be sold only in the state of California, and will not be distributed through interstate commerce, then California would be the approving body. According to the DPH, this has resulted in a few instances where California has approved a new drug or device application.
Independent from drug or device applications, manufacturers of drugs
and devices must be licensed to manufacture in the state of
California. The FDA does not approve manufacturers, but they do
conduct inspections to ensure manufacturers are in compliance with
good manufacturing practices. Under California Law, drug
manufacturers must be licensed with the DPH even if not registered
with FDA.
Clinical Trials. A clinical trial is a study that is carefully designed to test the benefits and risks of a specific medical treatment or intervention, such as a new drug. The FDA requires a multi-phase clinical trials process to be completed before deciding if an investigational medicine is safe and effective for a broader patient population.
According to the author’s office, the FDA has been having great
difficulty in getting patients to participate in clinical trials of
investigational drugs, because patients do not want to take the
chance that they will be in the control group and not receive the
experimental drug.
Expanded Access. If a patient is unable to enroll in a
clinical trial, the FDA expanded access exemption, also commonly
referred to as “compassionate use,” provides a pathway for
patients to gain access to investigational drugs or devices for
serious diseases or conditions. A licensed physician is able to
apply for expanded access under a single patient IND Application on
behalf of the patient. The supervising physician must be willing to
commit to oversee the treatment, work with the manufacturing company
and the FDA, obtain the drugs, monitor the patient during the course
of treatment, and file necessary paperwork. The FDA states that they
receive approximately 1,000 expanded use applications per year, and
has approved more than 99% of those applications. In the last four
years, the FDA has denied only 33 of nearly 6,000 expanded access
requests.
The FDA allows physicians to request expanded access for patients in an emergency situation over the phone or by "other rapid means of communication." The FDA states that authorization of the emergency use may be given by an FDA official over the telephone, provided the physician explains how the expanded access use will meet federal requirements for expanded access use and agrees to submit an expanded access submission within 15 working days of FDA’s initial authorization of the expanded access use.
Critics of the FDA process have raised concerns that the expanded
access application is too cumbersome for physicians and patients to
complete. On February 4, 2015, the FDA announced that it would be
streamlining the expanded use application process, and stated that
the proposed application will allow physicians to apply for
experimental drugs in just 45 minutes. The FDA draft guidance on the
new application process is currently in the 60-day public comment
period.
Institutional Review Board (IRB). Any FDA expanded access requests for any investigational drug must be reviewed by an IRB in order to understand the risks of an experimental treatment and ensure that the patient understands them as well.
A physician submits the proposed experimental protocol, to an IRB,
which reviews them to make sure patients are fully aware of potential
risks and are willing to accept the level of potential risk
associated with the drug. IRBs are usually associated with a
hospital or research institution, but there are independent IRBs
available for physicians not associated with such an institution.
Physicians are governed primarily by the IRB committee policies set
up by their specific institution. The FDA maintains
the right to overrule the physician and IRB.
Physician Liability and Enforcement Action Against a Physician. Physicians may be concerned about facing a liability risk for investigational drugs, biological products or devices that they recommend to patients or help them gain access to. The Compassionate Access Act of 2010 (H.R. 4732) sought to address this issue by providing immunity to the manufacturer, distributor, administrator, sponsor or physician from suit or liability.
If AB 159 is enacted, the MBC and OMB would be prohibited from taking action against physician’s license for prescribing or treating a patient with an investigational drug, biological product or device.
Other States. Similar legislation has been signed into law in
the following states: 1) Colorado, 2) Louisiana, 3) Michigan and 4)
Missouri. Arizona adopted a resolution to place the issue on the
November 2014 ballot, where it was approved by voters. Presently, at
least 20 other states are considering similar legislation.
Prior Related Legislation. SB 128 (Wolk) of the current legislative session, permits a competent, qualified individual who is a terminally ill adult to receive a prescription for aid in dying medication if certain conditions are met. STATUS: This bill is currently pending in the Senate Appropriations Committee.
SB 149 (Stone) of the current legislative session, is largely similar to this bill, with differences primarily in definitions and liability exemptions. STATUS: SB 149 is pending in the Senate Business, Professions and Economic Development Committee.
SB 715 (Anderson) of the current legislative session, is largely the same as this bill with some differences in definitions. STATUS: SB 715 is pending in the Senate Health Committee.
ARGUMENTS IN SUPPORT:
The Los Angeles County Board of Supervisors writes in its letter of support, “Five states, Colorado, Louisiana, Missouri, Michigan and Arizona, have recently enacted bi-partisan legislation or voter-approved ballot initiatives to establish “Right to Try” laws. Terminally ill patients, who have exhausted their options to find a cure and who have identified a physician and pharmaceutical company willing to assist them, deserve the right to experimental treatments that could prolong their lives.”
ARGUMENTS IN OPPOSITION:
The California Medical Association opposes the bill and writes, “While we appreciate the good intentions behind the bill, we have significant patient safety concerns with allowing access to unproven drugs outside of the FDA’s clinical trials and compassionate use programs. The FDA ensures efficacy and safety of using such drugs, and once they are removed from these processes there is no longer an ability to protect patients and provide proper oversight…In addition, since state law can’t supersede federal law, companies may not want to provide their treatments outside of FDA processes. The key to current processes is that they be uniformly regulated and monitored to ensure both proper participation and consumer protection.”
The California Nurses Association/National Nurses United opposes the bill and writes in their letter, “While apparently well meaning, this legislation promises vulnerable patients and their families that there will be a state program for obtaining drugs that is similar to the FDA expanded access program only shorter. This short cut is purportedly a means of increasing access to drugs and devices for terminally ill patients. This bill would prohibit the Medical Board of California and the Osteopathic Medical Board of California from taking any disciplinary action against the license of a physician based solely on the physician’s recommendation to an eligible patient for prescription or treatment with the investigations drug or device. This bill also purports to provide protection by prohibiting a state agency from altering any recommendation made to the federal Medicare and Medicaid program for these activities.”
The Association of Northern California Oncologists (ANCO) also opposes the bill and states, “The ANCO Board cited several reasons to oppose AB 159, including the difficulty of identifying “terminally-ill” patient, the danger a “right to try” outside the context of a clinical trial would present to adult clinical trial enrollment, the lack of an informed consent process to protect patients seeking investigational drugs, and the lack of appropriate physician supervision of the use of these drugs. Despite very low adult clinical trial enrollments, this nation’s clinical trial system has resulted in the relatively rapid evolution of cancer care. Any threat to adult clinical trial enrollment would result in slowing the development of cancer care in the future.”
AMENDMENTS:
As was noted in the Assembly Committee on Health’s analysis, the bill does not require any agency or company to track whether patients are able to acquire the experimental drugs or devices they are seeking. As such, the author should require the IRB to send a report of the status or results of requests made, the duration of treatments and costs paid by patients for the experimental drugs or devices to the DPH, the MBC and the OMB.
On page 6, after line 36 add the following:
(b) The physician’s institutional review board or an accredited institutional review board is required to send a bi-annual report to the Department of Public Health, the Medical Board of California and the Osteopathic Medical Board with the following information:
The number of requests made
The status of the requests made
The duration of treatment
The costs of the treatment paid by patients
The bill specifies that a physician may prescribe a drug, “provided that the recommendation or prescription is consistent with the medical standards of care.” However, when a physician prescribes a medication for off-label use, they are inherently deviating from the standards of care. Thus, the language of the bill should specify that the standards of care that the physician is adhering to are those that are approved by the institutional review board. To this end, the author should amend the bill as follows:
On page 6, line 36, strike the following, medical standards
of care and insert the following, protocol as approved
by the institutional review board.
As has been done in other states that have proposed similar legislation, the author should address the premature ending of a clinical trial.
On page 6, line 25, add the following:
If the clinical trial is closed due to the lack of efficacy or toxicity, the drug must not be offered. If notice is given on a drug, product or device taken by a patient outside of a clinical trial, the pharmaceutical company and the patient’s physician must notify the patient of the information from the safety committee of the clinical trial.
In order to confirm the patient’s diagnosis of a terminal illness, the author should amend the bill to require the primary physician to retain verification from a consulting physician of the patient’s diagnosis and prognosis.
On page 3, line 22, add the following after “her”:
primary physician and a consulting physician
On page 3, line 29, add the following after “her”:
primary physician and a consulting physician
On page 4, line 17, add:
“Primary
“Pphysician”
On page 4, after line 19 add the following:
“Consulting physician” means a physician and surgeon licensed under the Medical Practice Act or an osteopathic physician and surgeon licensed under the Osteopathic Act who shall perform all of the following
(a) Examine the qualified individual and his or her relevant medical records.
(b) Confirm in writing the attending physician’s diagnosis and prognosis.
(c) Verify, in the opinion of the consulting physician, that the eligible patient is competent, acting voluntarily, and has made an informed decision.
REGISTERED SUPPORT:
Los Angeles County Board of Supervisors
REGISTERED OPPOSITION:
California Medical Association
California Nurse Association/National Nurses United
Association of Northern California Oncologists
Analysis Prepared by: Le Ondra Clark Harvey, Ph.D. / B. & P. / (916) 319-3301
AB 159
Page 10
Date of Hearing: April 7, 2015
ASSEMBLY COMMITTEE ON HEALTH
Bonta, Chair
AB 159
(Calderon) – As Introduced January 21, 2015
SUBJECT:
Investigational drugs, biological products, and devices
SUMMARY:
Permits a manufacturer of a drug, biological product, or device (experimental drug or device) that has not yet received federal or state approval to market to make the product available to eligible patients with terminal illnesses, as specified. Specifically, this bill:
Allows, but does not require, the manufacturer of an experimental drug or device to provide an investigational drug or device to an eligible patient, as defined. Specifies that the manufacturer may provide for free, or may charge the patient to pay for the costs of the drug or device.
Defines an eligible patient as one who has met all the following criteria:
Has a terminal illness, defined as a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely;
Has considered all other treatment options currently approved by the U.S. Food and Drug Administration (FDA);
Has been unable to participate in a clinical trial within 100 miles of their home, or has not been accepted, as specified;
Has received recommendation from their physician for the drug or device;
Has given written, informed consent, as specified; and,
Has documentation form their physician attesting that the patient has met these requirements.
Allows, but does not require, a health plan to provide coverage for the drug or device, or the costs of services related to the use of the drug or device.
Prohibits a state regulatory board form revoking, failing to renew, or taking any other disciplinary action against a physician's license based on the recommendation, prescription, or treatment of the drug or device, provided the recommendation or prescription is consistent with the medical standards of care.
Prohibits a state agency from altering a recommendation made to the federal Centers for Medicare and Medicaid Services regarding a health care provider’s certification to participate in the Medicare or Medicaid program based solely on the recommendation from an individual health care provider that a patient have access to the drug or device.
Prohibits an official, employee, or agent of the state from blocking or attempting to block an eligible patient’s access to an investigational drug or device pursuant to this article. Specifies that counseling, advice, or a recommendation consistent with medical standards of care from a licensed healthcare provider is not a violation of this section.
Specifies that this article does not create a private cause of action against a manufacturer of an investigational drug or device, or against any other person or entity involved in the care of an eligible patient using the drug or device, for any harm done to the patient resulting from the drug or device, so long as the manufacturer or other person or entity is complying in good faith with the terms of this article, unless there was a failure to exercise reasonable care.
EXISTING STATE LAW:
Establishes the Sherman Food, Drug, and Cosmetic Law, which regulates the packaging, labeling, and advertising of drugs and devices, administered by the Department of Public Health (DPH).
Prohibits, in the Sherman Law, the sale, delivery, or giving away of a new drug or device unless it is either
A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval; or,
A new drug, and a new drug application has been approved for it by the FDA, pursuant to federal law, or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated, or suspended under the FDA.
Establishes the Protection of Human Subjects in Medical Experimentation Act which prescribes various protections for subjects of medical experimentation relating to a bill of rights; informed consent procedures and documentation; and, the provision of specified disclosures, including the right for a subject to give or withdraw consent freely and without duress. Imposes penalties for violations of these protections.
Requires health plans and insurers to provide an external, independent review process to examine plan’s coverage denials of experimental or investigational therapies for individual enrollees who have a life-threatening or seriously debilitating condition and who meet other specified criteria.
Requires health plans and insurers to provide coverage for all routine patient care costs relative to the treatment of an enrollee or insured diagnosed with cancer and accepted in an FDA-approved cancer clinical trial, Phase I-IV, if the enrollee's treating physician, recommends participation in the clinical trial after determining such participation has a meaningful potential to benefit the enrollee or insured.
EXISTING FEDERAL LAW:
Establishes the federal Food, Drug, and Cosmetic Act, which grants authority to the FDA to oversee the safety of food, drugs, and cosmetics.
Prohibits any new drug from being introduced into interstate commerce unless an application has been approved by the FDA.
Under federal regulation:
Requires clinical trial sponsors to submit an Investigational New Drug (IND) application to the FDA for clinical investigation of a new drug or new indication of an approved drug, with certain exceptions;
Requires review and approval from an Institutional Review Board (IRB) before a clinical study can be initiated under an IND;
Defines an IRB as an appropriately constituted group that has been designated to review and monitor biomedical research involving human subjects, to ensure that a clinical trial is ethical and that the rights of study participants are protected; and,
Authorizes an IRB to approve, require modifications in, or disapprove research, or to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects.
Establishes the Office for Human Research Protections (OHRP), which provides leadership in the protection of the rights, welfare, and wellbeing of subjects involved in research conducted or supported by the U.S. Department of Health and Human Services (HHS). OHRP helps ensure this by providing clarification and guidance, developing educational programs and materials, maintaining regulatory oversight, and providing advice on ethical and regulatory issues in biomedical and social-behavioral research.
FISCAL EFFECT:
This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
PURPOSE OF THIS BILL. According to the author, this bill removes barriers to accessing potentially life-saving drugs for terminally-ill patients and doctors who believe an investigational drug or device could be their last hope for survival. The author further states that those patients that have exhausted all other treatment options, and are not eligible for clinical trials, often seek access to INDs, but face a variety of hurdles. These patients may seek compassionate use exemptions from the FDA, but the process is cumbersome and approval comes too late for many. This bill removes barriers for patients who need to immediately obtain investigational treatments, while also protecting physicians, hospitals, and manufacturers from retribution.
BACKGROUND. Patient requests for access to drugs and biologics prior to their approval have long created a dilemma for regulators, who must balance the needs of patients and their families who believe that an experimental product could save their life, with ensuring the safety of the greater population through tightly controlled clinical trials and drug approval. This issue has become increasingly visible and difficult in recent times, as views about the inherent right of patients in certain situations to unapproved products have been expressed by patients and their advocates, state legislators, members of Congress, and some court cases. In 2014 four states adopted legislation similar to this bill (Colorado, Louisiana, Michigan, and Missouri) and one state (Arizona) adopted a resolution to place the issue on the November 2014 ballot, where it was approved by voters. To date, at least 20 states are considering similar legislation in 2015.
FDA AND STATE APPROVAL OF DRUGS. FDA has jurisdiction over all drugs that are sold across state lines. State law gives DPH the authority to approve for market a drug or device that is sold in California. If a product has received FDA approval, then DPH automatically recognizes the product's approval. In rare instances when a drug or device will be sold only in the state of California, and will not be distributed through interstate commerce, then California would be the approving body. According to DPH, this has resulted in a few instances where California has approved a new drug or device application.
Independent from drug or device applications, manufacturers of
drugs and devices must be licensed to manufacture in the state of
California. FDA does not approve manufacturers, but they do conduct
inspections to ensure manufacturers are in compliance with good
manufacturing practices. Under California Law, drug manufacturers
must be licensed with DPH even if not registered with FDA.
THE CLINICAL TRIAL PROCESS. A clinical trial is a study that is carefully designed to test the benefits and risks of a specific medical treatment or intervention, such as a new drug. The FDA requires a multi-phase clinical trials process to be completed before deciding if an investigational medicine is safe and effective for a broader patient population.
Phase I is a clinical trial using a small group of healthy individuals (generally 20 to 80 volunteers). This stage is designed to assess the toxicity and dosing of a drug and whether or not there are harmful side effects associated with the drug. Phase I trial does not establish either the safety or efficacy of a drug. According to the FDA, the goal in this phase is to determine what the drug's most frequent side effects are in healthy volunteers, how the drug is metabolized and excreted, and whether there is an unacceptable level of toxicity associated with taking the drug.
Phase II clinical trials involve control groups and experimental groups (up to 300 individuals total) to determine whether the drug is effective for the intended purpose on a particular disease or condition. This phase aims to obtain preliminary data on whether the drug works in people who have a certain disease or condition.
Phase III begins if the drug proves to be effective in Phase II. These studies gather further information on the drug’s safety and effectiveness on different populations (several hundred to about 3,000 participants) and tests varying levels of doses in combination or in comparison with different drugs.
Phase IV studies are post-marketing studies the sponsor has agreed to do after the FDA approves a drug. These studies gather additional information on a product’s safety, efficacy, and optimal use.
Expanded Access to investigational products through the FDA. If a patient is unable to enroll in a clinical trial, the FDA expanded access exemption, also called “compassionate use,” provides a pathway for patients to gain access to investigational drugs or devices for serious diseases or conditions. A licensed physician is able to apply for expanded access under a single patient IND Application on behalf of the patient. The supervising physician must be willing to commit to oversee the treatment, work with the manufacturing company and FDA, obtain the drugs, monitor the patient during the course of treatment, and file necessary paperwork. The FDA states that they receive approximately 1,000 expanded use applications per year, and has approved more than 99% of those applications. In the last four years, the FDA has denied only 33 of nearly 6,000 expanded access requests.
FDA directives allow physicians to request expanded access for patients in an emergency situation over the phone or by "other rapid means of communication." The FDA states that authorization of the emergency use may be given by an FDA official over the telephone, provided the physician explains how the expanded access use will meet federal requirements for expanded access use and agrees to submit an expanded access submission within 15 working days of FDA"s initial authorization of the expanded access use.
Critics of the FDA process have raised concerns that the Expanded Use application is too cumbersome for physicians and patients to complete. Critics claim that it currently requires an application that takes doctors 100 hours to fill out. The response time from the FDA ranges from a few days to a few months. On February 4, 2015, the FDA announced that it would be streamlining the expanded use application process, and stated that the proposed application will allow physicians to apply for experimental drugs in just 45 minutes. The FDA draft guidance on the new application process is currently in the 60-day public comment period.
Distinction from off-label prescribing. The FDA does not regulate the practice of medicine. After the FDA has approved a drug, a doctor is free to decide how to use it. A provider has the ability, under his/her medical license, to use an FDA-approved and legally-marketed drug or device to treat a patient, even if that treatment is outside of the product's FDA labeling, also known as "off-label" prescription. There are times, however, when a provider may think that the best possible treatment for a patient is a drug or medical device that is not yet FDA-approved or legally marketed in the United States. In such cases, a provider cannot write a prescription for or order the treatment through usual mechanisms, and the physician may seek to gain access for the patient through an existing clinical trial or using compassionate use exemptions. Compassionate use might also be sought for drugs and devices that are approved in other countries, but not within the United States.
COURT HISTORY. In 2005,the Abigail Alliance for Better Access to Developmental Drugs, with the mission of facilitating access to experimental drugs for patients, sued the FDA, claiming a constitutional due process right for terminally ill patients to access unapproved drugs. A US District court disagreed and the case was heard by the US Court of Appeals for the District of Columbia Circuit. In 2006, a divided three-judge panel of the D.C. Circuit agreed with the Alliance, finding that where there are no other FDA-approved treatment options, a terminally ill patient has a constitutionally-protected “fundamental right” to access investigational drugs. In 2007, the D.C. Circuit reheard the case “en banc” and reversed the panel decision. The Alliance then filed a petition asking the U.S. Supreme Court to hear the case but the Supreme Court denied the petition, so for now the Court of Appeals decision stands.
ENSURING PATIENT SAFEGUARDS THROUGH THE INSTITUTIONAL REVIEW BOARD PROCESS. Federal law requires that any FDA expanded use requests for any investigational drug be reviewed by an IRB, or ethics committee; a group of medical experts that evaluates the risks of an experimental treatment and ensures the patient understands them as well. The IRB process protects the people receiving the drug and ensures that the risks are reasonable given the potential benefits. A physician submits the proposed experimental protocol, including duration of treatment and the informed consent documents to an IRB, which reviews them to make sure patients are fully aware of potential risks and are willing to accept the level of potential risk associated with the drug. IRBs are usually associated with a hospital or research institution, but there are independent IRBs available for physicians not associated with such an institution. The OHRP requires and regulates the use of IRBs for any research supported or conducted by HHS (which includes National Institutes on Health funded research). While OHRP oversees IRB processes in general, each institution has their own review board, timelines, and specific policies. Physicians are governed primarily by the IRB committee policies set up by their specific institution.
CONTROVERSY OVER RESEARCH WITHOUT IRB APPROVAL. In 2012, two neurosurgeons from the University of California, Davis (UC Davis) were accused of performing an unapproved experimental procedure on three dying brain cancer patients. In these cases, the neurosurgeons obtained informed consent from the patients but did not communicate to the patients that the procedure had not been approved by the FDA as an investigational new treatment for testing in human subjects. The patients were also not informed that the research was not approved by UC Davis' IRB. Two of the patients developed sepsis and died within weeks of their surgeries. Both surgeons involved were banned from performing surgery and later resigned from the University. In response to these incidences, UC Davis has since tightened its innovated use policy to expressly prohibit any use of a non-FDA approved drug, biologic, or device without formal IRB and, as required, FDA approval, regardless of the purpose of the use.
Who will pay? If a patient is enrolled in an FDA-approved clinical trial for cancer, California law requires that the insurer pay for routine patient care costs. Health plans do not have to pay for experimental drug, but in most cases these drugs are given to clinical trial participants at no cost by the government agency, university medical center or pharmaceutical company that sponsors the trial.
This bill authorizes, but does not require any health plan, insurer, or manufacturer to pay for the cost of the medication. Typically, health plans limit coverage to only FDA approved drugs and devices. In addition, when a plan reviews potential drugs for their formulary, they review data on clinical effectiveness, cost of the drug, potential side effects or harm, and the costs associated with treating that. Under current law, a patient denied coverage for an experimental drug or device may appeal the decision and request evaluation by Independent Medical Review, although this can be a time-consuming process. Taken together, it is unlikely that health plans would cover the cost of experimental drugs obtained through this legislation.
In the expanded access use protocols the FDA allows, after their review and approval, the manufacturer to charge a nominal fee for the cost of providing the experimental drug or device. This bill authorizes a manufacturer to charge for the experimental drug or device, without any review or approval.
SUPPORT. Supporters argue that patients with no other treatment options should be able to take on more risk than healthy patients would otherwise choose. The Los Angeles County Board of Supervisors supports this bill, stating that terminally ill patients, who have exhausted their options to find a cure and who have identified a physician and pharmaceutical company willing to assist them, deserve the right to experimental treatments that could prolong their lives.
OPPOSITION. The Association of Northern California Oncologists opposes this bill citing several reasons, including the difficulty identifying "terminally-ill" patients, the lack of an informed consent process to protect patients seeking these drugs, and the lack of appropriate physician supervision of the use of these drugs. The California Medical Association states opposition due to significant patient safety concerns with allowing access to unproven drugs outside the FDA's clinical trials and compassionate use programs. The FDA ensures efficacy and safety of using such drugs, and once they are removed from these processes there is no longer an ability to protect patients and provide proper oversight. Additionally, this bill may be both premature and unnecessary, and could also potentially detract from the FDA rulemaking process that is currently ongoing. The California Nurses Association (CNA) states that this bill erroneously suggests that consumers do not have access to these drugs because physicians fear their liability to practice medicine would be compromised and their liability increased if they were to recommend such treatment. CNA points out that "nothing in this legislation impacts the availability of drugs to terminally ill patients unless the manufacturers of the drugs allow it to be used in advance of FDA approval".
STATEMENT OF CONCERN. The Pharmaceutical Research and Manufacturers Association (PhRMA) filed a letter of concern with this Committee, stating that Right-to-Try legislation, while well-intentioned, could have serious unintended consequences that must be taken into consideration. Robust clinical trials are one of the key elements in bringing new therapies to market. PhRMA states that it is imperative that investigational drugs be used within the boundaries of carefully constructed and monitored clinical trials to ensure patient safety, and to glean key understandings about the safety, efficacy, and uses of investigational drugs. Furthermore, PhRMA is concerned with the lack of oversight and accountability in this legislation. Both clinical trials and the FDA's expanded access program requires that patients be given these under the close supervisions of a physician and other health care providers to closely monitor patient reactions. Allowing blanket access to these drugs outside of monitored trials could yield catastrophic results for the patient.
RELATED LEGISLATION:
SB 128 (Wolk) permits a competent, qualified individual who is a terminally ill adult to receive a prescription for aid in dying medication if certain conditions are met. This bill was approved by the Senate Health Committee on March 17, 2015 and is currently pending in the Senate Judiciary Committee.
SB 149 (Stone) is largely similar to this bill, with differences primarily in definitions and liability exemptions. SB 149 is pending in Senate Health committee on April 15, 2015.
SB 715 (Anderson) is largely the same as this bill with some differences in definitions. SB 715 is pending in Senate Health committee on April 15, 2015.
POLICY COMMENTS.
Is this bill premature? In response to requests from advocates, and the passage of several right-to-try bills in states, the FDA is promulgating new regulations to dramatically shorten the length of time it takes to apply for expanded use access. The proposed regulations were announced on February 4th, 2015 and are currently open for public comment. Given that the FDA may arrive at the intended purpose of this goal in the very near future, the committee may wish to consider whether this bill is premature.
Will this bill achieve its intended goal? Shipping an investigational drug across state lines is illegal without an approved IND from the FDA. If a manufacturer agreed to provide their investigational drug to a patient under this bill, they would be in violation of federal law. Drug manufacturers are not exempted from FDA rules under this law, and therefore companies interested in gaining full regulatory approval for their products are unlikely to ignore federal regulation.
Similar bills in other states have been enacted too recently to assess their impact. Anecdotal news reports suggest that when approached by patients directly, manufacturers are requesting that they go through the FDA process instead.
How would we know is this policy is effective? The FDA tracks and provides data on how many expanded use exemptions they approved. Neither FDA nor any other entity, however, keeps track of how many requests are turned down by companies. Under this bill, the state would not know how many requests are being made to companies. The Committee may wish to consider whether it would be appropriate to require physicians report to an appropriate state agency the status of their request and use of the experimental drug. That would help the author/Legislature know if the policy is useful.
Is there adequate oversight? This bill does not specify who, if anyone, is responsible for overseeing the patient's progress after obtaining the drug or device. Under FDA's expanded access regulations, the manufacturer or treating physician submit a written summary of the results of the expanded access use, including any adverse events. Under this bill, it is not clear if the supervising physician or the manufacturer would have to notify the FDA of patient outcomes or adverse reactions. It is unclear if the physician would even have to notify the manufacturer.
Conflict with other bills this session. There are two other bills introduced this session that address this same issue. Assuming all the bills continue to move forward this year, subsequent amendments will be required.
SUGGESTED AMENDMENTS
Prognosis of terminal illness is a matter a clinical judgment; it is a subjective probability determined by the provider. Studies have shown that physicians are often not able to provide an accurate prognosis,1 and that accuracy diminishes as the length of time prior to projected death increases, a problem known as the horizon effect. Specifically, the ability to discriminate between patients who would survive for one year and those who would not has been found to be very poor.2 California statutes currently have several different, often inconsistent, definitions of terminal illness.
Additionally, the FDA does not specify terminal illness, and instead has a definition that is more expansive than this bill: "serious or immediately life-threatening disease or condition". For example, a patient diagnosed with Amyotrophic Lateral Sclerosis may have more than 5 years life expectancy from the date of diagnosis, but with serious impacts on day-to-day functioning, and could therefore apply for expanded access through the FDA but not through this bill. The author should strike the definition of terminal illness and instead use terminology consistent with the FDA expanded use exemptions. This would remove the need for a subjective definition of terminal illness, and offer parity with federal regulations on this same issue (CFR 21, Section 312.300).
"Immediately life-threatening disease or condition"
means a stage of disease in which there is reasonable likelihood that
death will occur within a matter of months or in which premature
death is likely without early treatment. "Serious disease or
condition" means a disease or condition associated with
morbidity that has substantial impact on day-to-day functioning.
“Terminal illness” means a disease that, without
life-sustaining procedures, will result in death in the near future
or a state of permanent unconsciousness from which recovery is
unlikely.
Similar laws in other states are too recent assess whether the laws are actually providing dying patients greater access to experimental drugs compared with what the FDA already permits. This bill does not require any agency or company to track whether patients are able to acquire the experimental drugs or devices they are seeking. The author should consider requiring reporting to an appropriate state agency the status or results of requests made, the duration of treatments, or costs paid by patients for the experimental drugs or devices.
Informed consent requirements for experimental treatments are already codified in the “Protection of Human Subjects in Medical Experimentation Act” (HSC 24170-24179). To remain consistent with the high standard of informed consent in current law, subdivision (g) should be amended to include the appropriate reference:
(g)… and attested to by the patient’s physician and a witness.
The written, informed consent shall be consistent with Chapter
1.3, Division 20 of the Health and Safety Code and, and do
all of the following:
Even when treating a single, terminally ill patient, the use of an unapproved drug is still considered human experimentation and should be bound by the highest scientific ethical standards. Lack of IRB oversight in this bill weakens patient protections. Most institutions have IRB policies in place that physicians must follow. Because this bill does not specify IRB review of treatment protocol and informed consent, physicians not bound and their institutional policies might not undergo this ethical review. This bill should be amended to include reference to IRB.
(g) “Written, informed consent” means a written document that has been approved by the physician's institutional review board or an accredited independent institutional review board, is signed by an eligible patient, or his or her legally authorized representative where the patient lacks the capacity to consent, and attested to by the patient’s physician and a witness.
REGISTERED SUPPORT / OPPOSITION:
Support
County of Los Angeles
Opposition
Association of Northern California Oncologists
California
Medical Association
California Nurses Association
Analysis Prepared by:
Dharia McGrew/HEALTH/(916) 319-2097
1 Glare, P., K. Virik, M. Jones, M. Hudson, S. Eychmuller, J. Simes, and N. Christakis. "A systematic review of physicians' survival predictions in terminally ill cancer patients." BMJ 327, no. 7408 (2003): 195.
2 Mackillop, William J., and Carol F. Quirt. "Measuring the accuracy of prognostic judgments in oncology." Journal of clinical epidemiology 50, no. 1 (1997): 21-29.
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Appropriations
Senate Standing Committee on Business, Professions and Economic Development
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Appropriations
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):